Demetri, George
eCommons Login: GDD1
first name: George
last name: Demetri
coauthor of: George, Suzanne
coauthor of: Fletcher, Jonathan
coauthor of: Wagner, Andrew
coauthor of: Van Den Abbeele, Annick
coauthor of: Raut, Chandrajit
full name: George Daniel Demetri, M.D.
has faculty rank: Full Professor
has network: selected publications
has network: research areas
has network: coauthor of
has network: similar to
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 10213
person in primary position: Professor of Medicine
physical neighbor: Campos, Susana
physical neighbor: Fisher, David
physical neighbor: Keskin, Derin
physical neighbor: Lee, Sandra
physical neighbor: McCleary, Nadine
similar to: Raut, Chandrajit
similar to: George, Suzanne
similar to: Fletcher, Jonathan
similar to: Hornick, Jason
similar to: Choueiri, Toni
type: Agent
type: Person
selected publications: Authorship 1851976
selected publications: Authorship 1794799
selected publications: Authorship 1824520
selected publications: Authorship 1734625
selected publications: Authorship 1733600
selected publications: Authorship 1668321
selected publications: Authorship 1647437
selected publications: Authorship 1642420
selected publications: Authorship 1640057
selected publications: Authorship 1601475
selected publications: Authorship 1586096
selected publications: Authorship 1570734
selected publications: Authorship 1500994
selected publications: Authorship 1498814
selected publications: Authorship 1497295
selected publications: Authorship 1491673
selected publications: Authorship 1458291
selected publications: Authorship 1439455
selected publications: Authorship 1451704
selected publications: Authorship 1431741
selected publications: Authorship 1404652
selected publications: Authorship 1400963
selected publications: Authorship 1378168
selected publications: Authorship 1365019
selected publications: Authorship 1352707
selected publications: Authorship 1349800
selected publications: Authorship 1351101
selected publications: Authorship 1346831
selected publications: Authorship 1349645
selected publications: Authorship 1344477
selected publications: Authorship 1328172
selected publications: Authorship 1320805
selected publications: Authorship 1316313
selected publications: Authorship 1313473
selected publications: Authorship 1308000
selected publications: Authorship 1293477
selected publications: Authorship 1284437
selected publications: Authorship 1257030
selected publications: Authorship 1243984
selected publications: Authorship 1235580
selected publications: Authorship 1231916
selected publications: Authorship 1233016
selected publications: Authorship 1225887
selected publications: Authorship 1234192
selected publications: Authorship 1215116
selected publications: Authorship 1210869
selected publications: Authorship 1223112
selected publications: Authorship 1223464
selected publications: Authorship 1223488

eCommons Login
tag name: catalyst:eCommonsLogin
type: DatatypeProperty

coauthor of
tag name: prns:coAuthorOf
type: ObjectProperty

end date
tag name: prns:endDate
type: DatatypeProperty

Faculty Rank
type: Class

full name
tag name: prns:fullName
type: DatatypeProperty

author list
tag name: prns:hasAuthorList
type: DatatypeProperty

has faculty rank
tag name: prns:hasFacultyRank
type: ObjectProperty

has network
tag name: prns:hasNetwork
type: ObjectProperty

published in
tag name: prns:hasPublicationVenue
type: DatatypeProperty

information resource reference
tag name: prns:informationResourceReference
type: DatatypeProperty

is primary position
tag name: prns:isPrimaryPosition
type: DatatypeProperty

latitude
tag name: prns:latitude
type: DatatypeProperty

longitude
tag name: prns:longitude
type: DatatypeProperty

photo
tag name: prns:mainImage
type: ObjectProperty

maximum weight
tag name: prns:maxWeight
type: DatatypeProperty

journal title abbreviation
tag name: prns:medlineTA
type: DatatypeProperty

MeSH DescriptorUI
tag name: prns:meshDescriptorUI
type: DatatypeProperty

MeSH semantic group name
tag name: prns:meshSemanticGroupName
type: DatatypeProperty

minimum weight
tag name: prns:minWeight
type: DatatypeProperty

number of authors
tag name: prns:numberOfAuthors
type: DatatypeProperty

number of connections
tag name: prns:numberOfConnections
type: DatatypeProperty

number of publications
tag name: prns:numberOfPublications
type: DatatypeProperty

Person ID
tag name: prns:personId
type: DatatypeProperty

person in primary position
tag name: prns:personInPrimaryPosition
type: ObjectProperty

physical neighbor
tag name: prns:physicalNeighborOf
type: ObjectProperty

position in department
tag name: prns:positionInDepartment
type: ObjectProperty

position in division
tag name: prns:positionInDivision
type: ObjectProperty

predicate node
tag name: prns:predicateNode
type: ObjectProperty

principal investigator name
tag name: prns:principalInvestigatorName
type: DatatypeProperty

publication date
tag name: prns:publicationDate
type: DatatypeProperty

similar to
tag name: prns:similarTo
type: ObjectProperty

sort order
tag name: prns:sortOrder
type: DatatypeProperty

start date
tag name: prns:startDate
type: DatatypeProperty

uniqueness weight
tag name: prns:uniquenessWeight
type: DatatypeProperty

year
tag name: prns:year
type: DatatypeProperty

Academic Article
type: Class

Article
type: Class

Document
type: Class

PubMed Identifier
tag name: bibo:pmid
type: DatatypeProperty

Address
type: Class

address line 1
tag name: vivo:address1
type: DatatypeProperty

address line 2
tag name: vivo:address2
type: DatatypeProperty

address line 3
tag name: vivo:address3
type: DatatypeProperty

city
tag name: vivo:addressCity
type: DatatypeProperty
type: FunctionalProperty

postal code
tag name: vivo:addressPostalCode
type: DatatypeProperty
type: FunctionalProperty

state or province
tag name: vivo:addressState
type: DatatypeProperty
type: FunctionalProperty

selected publications
tag name: vivo:authorInAuthorship
type: ObjectProperty

author rank in publication
tag name: vivo:authorRank
type: DatatypeProperty
type: FunctionalProperty

Authorship
type: Class

Department
type: Class

Division
type: Class

Grant
type: Class

research areas
tag name: vivo:hasResearchArea
type: ObjectProperty

research activities
tag name: vivo:hasResearcherRole
type: ObjectProperty

HR job title
tag name: vivo:hrJobTitle
type: DatatypeProperty

Information Resource
type: Class

linked author
tag name: vivo:linkedAuthor
type: ObjectProperty

linked information resource
tag name: vivo:linkedInformationResource
type: ObjectProperty

mailing address
tag name: vivo:mailingAddress
type: ObjectProperty

middle name or initial
tag name: vivo:middleName
type: DatatypeProperty
type: FunctionalProperty

positions
tag name: vivo:personInPosition
type: ObjectProperty

phone
tag name: vivo:phoneNumber
type: DatatypeProperty

Position
type: Class

position in organization
tag name: vivo:positionInOrganization
type: ObjectProperty

preferred title
tag name: vivo:preferredTitle
type: DatatypeProperty
type: FunctionalProperty

Researcher Role
type: Class

researcher role of
tag name: vivo:researcherRoleOf
type: ObjectProperty

contributes to
tag name: vivo:roleContributesTo
type: ObjectProperty

sponsor award id
tag name: vivo:sponsorAwardId
type: DatatypeProperty
type: FunctionalProperty

predicate
tag name: rdf:predicate
type: ObjectProperty

type
tag name: rdf:type
type: ObjectProperty

label
tag name: rdfs:label
type: DatatypeProperty

Concept
type: Class

Agent
type: Class

first name
tag name: foaf:firstName
type: DatatypeProperty
type: FunctionalProperty

last name
tag name: foaf:lastName
type: DatatypeProperty
type: FunctionalProperty

Organization
type: Class

Person
type: Class

Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature.
PubMed Identifier: 9690531
author list: Avigan D, Richardson P, Elias A, Demetri G, Shapiro M, Schnipper L, Wheeler C
published in: Cancer
information resource reference: Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998 Aug 01; 83(3):409-14.
journal title abbreviation: Cancer
publication date: 1998-08-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
PubMed Identifier: 11277174
author list: Elias AD, Richardson P, Avigan D, Ibrahim J, Joyce R, Demetri G, Levine J, Warren D, Arthur T, Reich E, Wheele C, Frei E, Ayash L
published in: Bone marrow transplantation
information resource reference: A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer. Bone Marrow Transplant. 2001 Feb; 27(3):269-78.
journal title abbreviation: Bone Marrow Transplant
publication date: 2001-02-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1048617
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
PubMed Identifier: 29466156
author list: Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM
published in: The New England journal of medicine
information resource reference: Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 02 22; 378(8):731-739.
journal title abbreviation: N Engl J Med
publication date: 2018-02-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN: Sarcoma.
PubMed Identifier: 11760565
author list: Demetri GD, Delaney T
published in: Cancer control : journal of the Moffitt Cancer Center
information resource reference: NCCN: Sarcoma. Cancer Control. 2001 Nov-Dec; 8(6 Suppl 2):94-101.
journal title abbreviation: Cancer Control
publication date: 2001-11-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
PubMed Identifier: 12228211
author list: Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002 Sep 15; 20(18):3898-905.
journal title abbreviation: J Clin Oncol
publication date: 2002-09-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).
PubMed Identifier: 15289315
author list: Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC, Corless CL, Demetri GD, Fletcher CD, Fletcher JA
published in: Cancer research
information resource reference: Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004 Aug 01; 64(15):5127-31.
journal title abbreviation: Cancer Res
publication date: 2004-08-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
PubMed Identifier: 15792913
author list: Desai J, Demetri GD
published in: Best practice & research. Clinical haematology
information resource reference: Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol. 2005; 18(3):389-406.
journal title abbreviation: Best Pract Res Clin Haematol
publication date: 2005-01-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 110064
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.

Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation.
PubMed Identifier: 7947240
author list: Ayash LJ, Elias A, Hunt M, Demetri G, Wheeler C, Tepler I, Schwartz G, Mazanet R, Reich E, McCauley M
published in: British journal of haematology
information resource reference: Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol. 1994 May; 87(1):153-61.
journal title abbreviation: Br J Haematol
publication date: 1994-05-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
PubMed Identifier: 8101563
author list: Tepler I, Cannistra SA, Frei E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J Clin Oncol. 1993 Aug; 11(8):1583-91.
journal title abbreviation: J Clin Oncol
publication date: 1993-08-01T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor.
PubMed Identifier: 9053480
author list: West DC, Grier HE, Swallow MM, Demetri GD, Granowetter L, Sklar J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J Clin Oncol. 1997 Feb; 15(2):583-8.
journal title abbreviation: J Clin Oncol
publication date: 1997-02-01T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk.
PubMed Identifier: 10506627
author list: Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CD, Singer S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol. 1999 Oct; 17(10):3252-9.
journal title abbreviation: J Clin Oncol
publication date: 1999-10-01T00:00:00
year: 1999
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of hematopoietic growth factors on the management of small-cell lung cancer.
PubMed Identifier: 8384974
author list: Demetri GD
published in: Chest
information resource reference: Impact of hematopoietic growth factors on the management of small-cell lung cancer. Chest. 1993 Apr; 103(4 Suppl):427S-432S.
journal title abbreviation: Chest
publication date: 1993-04-01T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.
PubMed Identifier: 8726588
author list: Demetri GD
published in: Pharmacotherapy
information resource reference: The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer. Pharmacotherapy. 1996 May-Jun; 16(3 Pt 2):94S-100S.
journal title abbreviation: Pharmacotherapy
publication date: 1996-05-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

The biology of GM-CSF: regulation of production and interaction with its receptor.
PubMed Identifier: 2157777
author list: Griffin JD, Cannistra SA, Sullivan R, Demetri GD, Ernst TJ, Kanakura Y
published in: International journal of cell cloning
information resource reference: The biology of GM-CSF: regulation of production and interaction with its receptor. Int J Cell Cloning. 1990 Jan; 8 Suppl 1:35-44; discussion 44-5.
journal title abbreviation: Int J Cell Cloning
publication date: 1990-01-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
PubMed Identifier: 17586092
author list: Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Fletcher JA, Pilotti S, Casali PG
published in: The Lancet. Oncology
information resource reference: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007 Jul; 8(7):595-602.
journal title abbreviation: Lancet Oncol
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeted approaches for the treatment of thrombocytopenia.
PubMed Identifier: 11700388
author list: Demetri GD
published in: The oncologist
information resource reference: Targeted approaches for the treatment of thrombocytopenia. Oncologist. 2001; 6 Suppl 5:15-23.
journal title abbreviation: Oncologist
publication date: 2001-01-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
PubMed Identifier: 12528773
author list: Demetri GD
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Eur J Cancer. 2002 Sep; 38 Suppl 5:S52-9.
journal title abbreviation: Eur J Cancer
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
PubMed Identifier: 19103723
author list: Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2009 Feb 10; 27(5):812-26.
journal title abbreviation: J Clin Oncol
publication date: 2008-12-22T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
PubMed Identifier: 19164557
author list: Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 03; 106(5):1542-7.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2009-01-21T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.
PubMed Identifier: 19391310
author list: Demetri GD
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST. Clin Adv Hematol Oncol. 2009 Feb; 7(2):S6-7.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2009-02-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 102900
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.
PubMed Identifier: 2685119
author list: Nakamura M, Merchav S, Carter A, Ernst TJ, Demetri GD, Furukawa Y, Anderson K, Freedman AS, Griffin JD
published in: Journal of immunology (Baltimore, Md. : 1950)
information resource reference: Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells. J Immunol. 1989 Dec 01; 143(11):3543-7.
journal title abbreviation: J Immunol
publication date: 1989-12-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
PubMed Identifier: 21177764
author list: Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011 Feb 15; 17(4):871-9.
journal title abbreviation: Clin Cancer Res
publication date: 2010-12-22T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).
PubMed Identifier: 15007386
author list: Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, Fletcher JA
published in: Oncogene
information resource reference: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene. 2004 May 13; 23(22):3999-4006.
journal title abbreviation: Oncogene
publication date: 2004-05-13T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.
PubMed Identifier: 15070666
author list: Bono P, Krause A, von Mehren M, Heinrich MC, Blanke CD, Dimitrijevic S, Demetri GD, Joensuu H
published in: Blood
information resource reference: Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood. 2004 Apr 15; 103(8):2929-35.
journal title abbreviation: Blood
publication date: 2004-01-08T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1027419
PubMed Identifier: 19652065
author list: Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009 Sep 01; 27(25):4188-96.
journal title abbreviation: J Clin Oncol
publication date: 2009-08-03T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.

Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level.
PubMed Identifier: 2647723
author list: Ernst TJ, Ritchie AR, Demetri GD, Griffin JD
published in: The Journal of biological chemistry
information resource reference: Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level. J Biol Chem. 1989 Apr 05; 264(10):5700-3.
journal title abbreviation: J Biol Chem
publication date: 1989-04-05T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Soft tissue sarcoma.
PubMed Identifier: 20581298
author list: Demetri GD, Antonia S, Benjamin RS, Bui MM, Casper ES, Conrad EU, DeLaney TF, Ganjoo KN, Heslin MJ, Hutchinson RJ, Kane JM, Letson GD, McGarry SV, O'Donnell RJ, Paz IB, Pfeifer JD, Pollock RE, Randall RL, Riedel RF, Schupak KD, Schwartz HS, Thornton K, von Mehren M, Wayne J
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Soft tissue sarcoma. J Natl Compr Canc Netw. 2010 Jun; 8(6):630-74.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2010-06-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.
PubMed Identifier: 19883316
author list: Ganjoo KN, Demetri GD, Jacobs C, Patel S
published in: Leukemia & lymphoma
information resource reference: Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. Leuk Lymphoma. 2009 Nov; 50(11):1882-4.
journal title abbreviation: Leuk Lymphoma
publication date: 2009-11-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.
PubMed Identifier: 19898902
author list: Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, Butrynski JE, Fletcher CD, Demetri GD, Bertagnolli MM
published in: Annals of surgical oncology
information resource reference: Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010 Feb; 17(2):407-15.
journal title abbreviation: Ann Surg Oncol
publication date: 2009-11-07T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.
PubMed Identifier: 21419930
author list: Blay JY, Demetri GD
published in: Seminars in oncology
information resource reference: The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction. Semin Oncol. 2011 Apr; 38 Suppl 1:S1-2.
journal title abbreviation: Semin Oncol
publication date: 2011-04-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
PubMed Identifier: 22425996
author list: Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, Gao P, Woo MS, Xu C, Yanagita M, Altabef A, Wang S, Lee C, Nakada Y, Peña CG, Sun Y, Franchetti Y, Yao C, Saur A, Cameron MD, Nishino M, Hayes DN, Wilkerson MD, Roberts PJ, Lee CB, Bardeesy N, Butaney M, Chirieac LR, Costa DB, Jackman D, Sharpless NE, Castrillon DH, Demetri GD, Jänne PA, Pandolfi PP, Cantley LC, Kung AL, Engelman JA, Wong KK
published in: Nature
information resource reference: A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18; 483(7391):613-7.
journal title abbreviation: Nature
publication date: 2012-03-18T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
PubMed Identifier: 17088579
author list: Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK
published in: Annals of internal medicine
information resource reference: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov 07; 145(9):660-4.
journal title abbreviation: Ann Intern Med
publication date: 2006-11-07T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.
PubMed Identifier: 18765557
author list: Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. Clin Cancer Res. 2008 Sep 01; 14(17):5626-34.
journal title abbreviation: Clin Cancer Res
publication date: 2008-09-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Imatinib targeting of KIT-mutant oncoprotein in melanoma.
PubMed Identifier: 19047099
author list: Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, Demetri GD, Widlund HR, Fisher DE, Hodi FS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008 Dec 01; 14(23):7726-32.
journal title abbreviation: Clin Cancer Res
publication date: 2008-12-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
PubMed Identifier: 19451429
author list: George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3154-60.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-18T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
PubMed Identifier: 19664491
author list: Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A
published in: Seminars in oncology
information resource reference: Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol. 2009 Aug; 36(4):302-11.
journal title abbreviation: Semin Oncol
publication date: 2009-08-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Soft tissue sarcoma clinical practice guidelines in oncology.
PubMed Identifier: 19817028
author list: Demetri GD, Baker LH, Beech D, Benjamin R, Casper ES, Conrad EU, DeLaney TF, Ettinger DS, Heslin MJ, Hutchinson RJ, Kiel K, Kraybill WG, Letson GD, Neff J, O'Donnell RJ, Paz IB, Pollock RE, Randall RL, Schupak KD, Tyler DS, von Mehren M, Wayne J
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Soft tissue sarcoma clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Mar; 3(2):158-94.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2005-03-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.
PubMed Identifier: 12846423
author list: Burstein HJ, Demetri GD, Mueller E, Sarraf P, Spiegelman BM, Winer EP
published in: Breast cancer research and treatment
information resource reference: Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.
journal title abbreviation: Breast Cancer Res Treat
publication date: 2003-06-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1070751
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.

Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.
PubMed Identifier: 29866822
author list: Hemming ML, Lawlor MA, Zeid R, Lesluyes T, Fletcher JA, Raut CP, Sicinska ET, Chibon F, Armstrong SA, Demetri GD, Bradner JE
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. Proc Natl Acad Sci U S A. 2018 06 19; 115(25):E5746-E5755.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2018-06-04T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Myeloid growth factors. Clinical practice guidelines in oncology.
PubMed Identifier: 17335688
author list: Crawford J, Althaus B, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Heaney ML, Htoy S, Kloth DD, Lyman GH, Messersmith WA, Michaud LB, Miyata SC, Robbins A, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):188-202.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2007-02-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1052797
PubMed Identifier: 18235122
author list: Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, Raymond AK, Bramwell VH, Baker LH, Maki RG, Tanaka M, Hecht JR, Heinrich MC, Fletcher CD, Crowley JJ, Borden EC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008 Feb 01; 26(4):626-32.
journal title abbreviation: J Clin Oncol
publication date: 2008-02-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations.
PubMed Identifier: 1509275
author list: Demetri GD, Antman KH
published in: Seminars in oncology
information resource reference: Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations. Semin Oncol. 1992 Aug; 19(4):362-85.
journal title abbreviation: Semin Oncol
publication date: 1992-08-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN Task Force report: gastrointestinal stromal tumor (GIST).
PubMed Identifier: 23570095
author list: Demetri G, DeMatteo RP
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN Task Force report: gastrointestinal stromal tumor (GIST). J Natl Compr Canc Netw. 2004 Sep; 2 Suppl 3:S-25-8.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2004-09-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
PubMed Identifier: 18270341
author list: Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD
published in: Journal of the National Cancer Institute
information resource reference: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib. J Natl Cancer Inst. 2008 Feb 20; 100(4):282-4.
journal title abbreviation: J Natl Cancer Inst
publication date: 2008-02-12T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1064581
PubMed Identifier: 22395976
author list: Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL
published in: Annals of surgical oncology
information resource reference: Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012 Jul; 19(7):2420.
journal title abbreviation: Ann Surg Oncol
publication date: 2012-07-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Erratum to: Phase II Trial of Neoadjuvant/adjuvant Imatinib Mesylate for Advanced Primary and Metastatic/recurrent Operable Gastrointestinal Stromal Tumors: Long-term Follow-up Results of Radiation Therapy Oncology Group 0132.

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.
PubMed Identifier: 22570147
author list: Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD
published in: Cancer
information resource reference: A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer. 2012 Nov 01; 118(21):5403-13.
journal title abbreviation: Cancer
publication date: 2012-05-08T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 104725
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

Molecular basis for sunitinib efficacy and future clinical development.
PubMed Identifier: 17690708
author list: Faivre S, Demetri G, Sargent W, Raymond E
published in: Nature reviews. Drug discovery
information resource reference: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov. 2007 Sep; 6(9):734-45.
journal title abbreviation: Nat Rev Drug Discov
publication date: 2007-09-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
PubMed Identifier: 18083403
author list: Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH
published in: Lancet (London, England)
information resource reference: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007 Dec 15; 370(9604):2011-9.
journal title abbreviation: Lancet
publication date: 2007-12-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
PubMed Identifier: 19862817
author list: Sonis S, Treister N, Chawla S, Demetri G, Haluska F
published in: Cancer
information resource reference: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010 Jan 01; 116(1):210-5.
journal title abbreviation: Cancer
publication date: 2010-01-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
PubMed Identifier: 20979472
author list: Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N, Kwak EL, Clark JW, Wilner KD, Christensen JG, Jänne PA, Maki RG, Demetri GD, Shapiro GI
published in: The New England journal of medicine
information resource reference: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010 Oct 28; 363(18):1727-33.
journal title abbreviation: N Engl J Med
publication date: 2010-10-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
PubMed Identifier: 22357255
author list: Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol. 2012 Jul; 23(7):1680-7.
journal title abbreviation: Ann Oncol
publication date: 2012-02-21T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1087408
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/108382492

Authorship 1086752
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
PubMed Identifier: 30081867
author list: Papadopoulos KP, Ben-Ami E, Patnaik A, Trone D, Li J, Demetri GD
published in: BMC cancer
information resource reference: Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial. BMC Cancer. 2018 Aug 06; 18(1):790.
journal title abbreviation: BMC Cancer
publication date: 2018-08-06T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/108382492
PubMed Identifier: 30084934
author list: Jones RL, Demetri GD, Schuetze SM, Milhem M, Elias A, Van Tine BA, Hamm J, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Patel S, von Mehren M
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Ann Oncol. 2018 09 01; 29(9):1995-2002.
journal title abbreviation: Ann Oncol
publication date: 2018-09-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.
PubMed Identifier: 8677444
author list: Demetri GD
published in: Seminars in oncology
information resource reference: High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Semin Oncol. 1996 Jun; 23(3 Suppl 6):22-6.
journal title abbreviation: Semin Oncol
publication date: 1996-06-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Chemotherapy and neutropenia.
PubMed Identifier: 8707761
author list: Kim SK, Demetri GD
published in: Hematology/oncology clinics of North America
information resource reference: Chemotherapy and neutropenia. Hematol Oncol Clin North Am. 1996 Apr; 10(2):377-95.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 1996-04-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
PubMed Identifier: 21484250
author list: Le Cesne A, Yovine A, Blay JY, Delaloge S, Maki RG, Misset JL, Frontelo P, Nieto A, Jiao JJ, Demetri GD
published in: Investigational new drugs
information resource reference: A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs. 2012 Jun; 30(3):1193-202.
journal title abbreviation: Invest New Drugs
publication date: 2011-04-12T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical presentation and management of mTOR inhibitor-associated stomatitis.
PubMed Identifier: 21890398
author list: de Oliveira MA, Martins E Martins F, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS
published in: Oral oncology
information resource reference: Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol. 2011 Oct; 47(10):998-1003.
journal title abbreviation: Oral Oncol
publication date: 2011-09-03T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.
PubMed Identifier: 2499657
author list: Brouckaert P, Spriggs DR, Demetri G, Kufe DW, Fiers W
published in: The Journal of experimental medicine
information resource reference: Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med. 1989 Jun 01; 169(6):2257-62.
journal title abbreviation: J Exp Med
publication date: 1989-06-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
PubMed Identifier: 20048174
author list: Wagner AJ, Malinowska-Kolodziej I, Morgan JA, Qin W, Fletcher CD, Vena N, Ligon AH, Antonescu CR, Ramaiya NH, Demetri GD, Kwiatkowski DJ, Maki RG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010 Feb 10; 28(5):835-40.
journal title abbreviation: J Clin Oncol
publication date: 2010-01-04T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Disease state awareness in sarcoma.
PubMed Identifier: 20966890
author list: Demetri GD
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Disease state awareness in sarcoma. Clin Adv Hematol Oncol. 2010 Aug; 8(8):543-5.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2010-08-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.
PubMed Identifier: 8150782
author list: Demetri GD
published in: Hematology/oncology clinics of North America
information resource reference: The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer. Hematol Oncol Clin North Am. 1994 Feb; 8(1):233-49.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 1994-02-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Cancer- and treatment-related anemia.
PubMed Identifier: 16316613
author list: Rodgers GM, Cella D, Chanan-Khan A, Chesney C, Cleeland C, Coccia PF, Demetri GD, Djulbegovic B, Garst JL, Gore M, Kraut EH, Lin WC, Millenson M, Mock V, Reinke D, Rosenthal J, Sabbatini P
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Cancer- and treatment-related anemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):772-89.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2005-11-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
PubMed Identifier: 16503137
author list: George S, Desai J, Paul Eder J, Manola J, Ryan DP, Appleman LJ, Demetri GD
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours. Eur J Cancer. 2006 May; 42(7):864-70.
journal title abbreviation: Eur J Cancer
publication date: 2006-02-28T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Markers of angiogenesis and clinical features in patients with sarcoma.
PubMed Identifier: 17265525
author list: DuBois S, Demetri G
published in: Cancer
information resource reference: Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 2007 Mar 01; 109(5):813-9.
journal title abbreviation: Cancer
publication date: 2007-03-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.
PubMed Identifier: 8648375
author list: Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol. 1996 Apr; 14(4):1201-8.
journal title abbreviation: J Clin Oncol
publication date: 1996-04-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
PubMed Identifier: 18955458
author list: Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008 Nov 20; 26(33):5352-9.
journal title abbreviation: J Clin Oncol
publication date: 2008-10-27T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.
PubMed Identifier: 18981463
author list: Baker LH, Rowinsky EK, Mendelson D, Humerickhouse RA, Knight RA, Qian J, Carr RA, Gordon GB, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. J Clin Oncol. 2008 Dec 01; 26(34):5583-8.
journal title abbreviation: J Clin Oncol
publication date: 2008-11-03T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
PubMed Identifier: 19647426
author list: Raut CP, Nucci MR, Wang Q, Manola J, Bertagnolli MM, Demetri GD, Morgan JA, Muto MG, Fletcher CD, George S
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. Eur J Cancer. 2009 Nov; 45(16):2818-24.
journal title abbreviation: Eur J Cancer
publication date: 2009-07-31T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
PubMed Identifier: 19723647
author list: Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2009 Sep 15; 15(18):5910-6.
journal title abbreviation: Clin Cancer Res
publication date: 2009-09-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1126017
PubMed Identifier: 22240283
author list: Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, Smethurst DP, Bray S, Hei YJ, Blay JY
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer. 2012 Mar; 48(4):547-63.
journal title abbreviation: Eur J Cancer
publication date: 2012-01-11T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study.

Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.
PubMed Identifier: 22726733
author list: McCarter MD, Antonescu CR, Ballman KV, Maki RG, Pisters PW, Demetri GD, Blanke CD, von Mehren M, Brennan MF, McCall L, Ota DM, DeMatteo RP
published in: Journal of the American College of Surgeons
information resource reference: Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence. J Am Coll Surg. 2012 Jul; 215(1):53-9; discussion 59-60.
journal title abbreviation: J Am Coll Surg
publication date: 2012-07-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.
PubMed Identifier: 7490240
author list: Demetri GD, Elias AD
published in: Hematology/oncology clinics of North America
information resource reference: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995 Aug; 9(4):765-85.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 1995-08-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.
PubMed Identifier: 10702394
author list: Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA
published in: The American journal of pathology
information resource reference: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000 Mar; 156(3):791-5.
journal title abbreviation: Am J Pathol
publication date: 2000-03-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
PubMed Identifier: 11032599
author list: Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Somerfield MR
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol. 2000 Oct 15; 18(20):3558-85.
journal title abbreviation: J Clin Oncol
publication date: 2000-10-15T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
PubMed Identifier: 11094323
author list: Goss G, Demetri G
published in: Surgical oncology
information resource reference: Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol. 2000 Aug; 9(2):53-9.
journal title abbreviation: Surg Oncol
publication date: 2000-08-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.
PubMed Identifier: 7857146
author list: Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ
published in: Annals of surgery
information resource reference: Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann Surg. 1995 Feb; 221(2):185-95.
journal title abbreviation: Ann Surg
publication date: 1995-02-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
PubMed Identifier: 12490740
author list: Ryan DP, Puchalski T, Supko JG, Harmon D, Maki R, Garcia-Carbonero R, Kuhlman C, Winkelman J, Merriam P, Quigley T, Jimeno J, Manola J, Demetri GD
published in: The oncologist
information resource reference: A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist. 2002; 7(6):531-8.
journal title abbreviation: Oncologist
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
PubMed Identifier: 15084621
author list: Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15; 22(8):1480-90.
journal title abbreviation: J Clin Oncol
publication date: 2004-04-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy.
PubMed Identifier: 15480688
author list: Nikolaidis P, Silverman SG, Cibas ES, Vansonnenberg E, Rybicki FJ, Manola JB, Tuncali K, Karshbaum SH, Singer S, Fletcher CD, Demetri GD
published in: European radiology
information resource reference: Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy. Eur Radiol. 2005 Feb; 15(2):383-9.
journal title abbreviation: Eur Radiol
publication date: 2004-10-06T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
PubMed Identifier: 16505440
author list: Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006 Mar 01; 24(7):1195-203.
journal title abbreviation: J Clin Oncol
publication date: 2006-03-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
PubMed Identifier: 17046465
author list: Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG
published in: Lancet (London, England)
information resource reference: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14; 368(9544):1329-38.
journal title abbreviation: Lancet
publication date: 2006-10-14T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.
PubMed Identifier: 2506316
author list: Demetri GD, Spriggs DR, Sherman ML, Arthur KA, Imamura K, Kufe DW
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo. J Clin Oncol. 1989 Oct; 7(10):1545-53.
journal title abbreviation: J Clin Oncol
publication date: 1989-10-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
PubMed Identifier: 22605650
author list: Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD
published in: Cancer
information resource reference: Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 01; 118(23):5894-902.
journal title abbreviation: Cancer
publication date: 2012-05-17T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
PubMed Identifier: 23117071
author list: Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, Judson I, von Mehren M, Schöffski P, Verweij J, Casali P, Rodenhuis S, Schütte HJ, Cassar A, Gomez J, Nieto A, Zintl P, Pontes MJ, Le Cesne A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013 Feb; 24(2):537-542.
journal title abbreviation: Ann Oncol
publication date: 2012-11-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.
PubMed Identifier: 7540124
author list: Demetri GD
published in: Chest
information resource reference: Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy. Chest. 1995 Jun; 107(6 Suppl):255S-260S.
journal title abbreviation: Chest
publication date: 1995-06-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource

Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.
PubMed Identifier: 14676103
author list: Mace JR, Keohan ML, Bernardy H, Junge K, Niebch G, Romeis P, Thoma A, Wagner T, Mueller U, Demetri G, Baker LH
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5829-34.
journal title abbreviation: Clin Cancer Res
publication date: 2003-12-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.
PubMed Identifier: 14770445
author list: Hesketh PJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, Colowick A, Schwartzberg L, Bertoli LF, Cole JT, Demetri G, Dessypris E, Dobbs T, Eisenberg P, Fleischman R, Hall J, Hoffman PC, Laber DA, Leonard J, Lester EP, McCachren S, McMeekin S, Meza L, Miller DS, Nand S, Oliff I, Paroly W, Pawl L, Perez A, Raftopoulos H, Rigas J, Rowland K, Scullin DC, Tezcan H, Waples J, Ward J, Yee LK
published in: Cancer
information resource reference: A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies. Cancer. 2004 Feb 15; 100(4):859-68.
journal title abbreviation: Cancer
publication date: 2004-02-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1124733
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.

Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition.
PubMed Identifier: 30630822
author list: Hemming ML, Lawlor MA, Andersen JL, Hagan T, Chipashvili O, Scott TG, Raut CP, Sicinska E, Armstrong SA, Demetri GD, Bradner JE
published in: Cancer research
information resource reference: Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. Cancer Res. 2019 03 01; 79(5):994-1009.
journal title abbreviation: Cancer Res
publication date: 2019-01-10T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Major response to imatinib mesylate in KIT-mutated melanoma.
PubMed Identifier: 18421059
author list: Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Van den Abbeele AD, Velazquez EF, Demetri GD, Fisher DE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008 Apr 20; 26(12):2046-51.
journal title abbreviation: J Clin Oncol
publication date: 2008-04-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.
PubMed Identifier: 23403628
author list: Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res. 2013 Feb 15; 19(4):909-19.
journal title abbreviation: Clin Cancer Res
publication date: 2013-02-12T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1177148
PubMed Identifier: 7521785
author list: Salgia R, Demetri GD, Kaplan WD
published in: Cancer
information resource reference: Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report. Cancer. 1994 Oct 01; 74(7):1887-90.
journal title abbreviation: Cancer
publication date: 1994-10-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Changes in Tc-99m radionuclide bone scan images and peripheralization of marrow hematopoietic activity associated with the administration of granulocyte colony stimulating factor as an adjunct to dose-intensified chemotherapy for breast cancer. A case report.

Beyond supportive care: what are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy?
PubMed Identifier: 7691255
author list: Demetri GD
published in: Blood
information resource reference: Beyond supportive care: what are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy? Blood. 1993 Oct 15; 82(8):2278-80.
journal title abbreviation: Blood
publication date: 1993-10-15T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.
PubMed Identifier: 7934135
author list: Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D
published in: Leukemia research
information resource reference: Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res. 1994 Oct; 18(10):769-76.
journal title abbreviation: Leuk Res
publication date: 1994-10-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.
PubMed Identifier: 8614968
author list: Webb IJ, Eickhoff CE, Elias AD, Ayash LJ, Wheeler CA, Schwartz GN, Demetri GD, Anderson KC
published in: Transfusion
information resource reference: Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections. Transfusion. 1996 Feb; 36(2):160-7.
journal title abbreviation: Transfusion
publication date: 1996-02-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.
PubMed Identifier: 8676090
author list: Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ
published in: The Journal of experimental medicine
information resource reference: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo. J Exp Med. 1996 Jun 01; 183(6):2681-6.
journal title abbreviation: J Exp Med
publication date: 1996-06-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 120631
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.

Authorship 1138184
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
PubMed Identifier: 30792533
author list: Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA
published in: British journal of cancer
information resource reference: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 03; 120(6):612-620.
journal title abbreviation: Br J Cancer
publication date: 2019-02-22T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Antineoplastic Agents, Alkylating
MeSH DescriptorUI: D018906
MeSH semantic group name: Chemicals & Drugs
number of authors: 309
number of publications: 620
uniqueness weight: 0.739775
type: Concept

Authorship 11315
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/938640

Pyrimidines
MeSH DescriptorUI: D011743
MeSH semantic group name: Chemicals & Drugs
number of authors: 1175
number of publications: 3428
uniqueness weight: 0.402661
type: Concept

Piperazines
MeSH DescriptorUI: D010879
MeSH semantic group name: Chemicals & Drugs
number of authors: 969
number of publications: 2695
uniqueness weight: 0.462139
type: Concept

Authorship 1142630
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Evolution of the International Sarcoma Community: A Personal Perspective.

Evolution of the International Sarcoma Community: A Personal Perspective.
PubMed Identifier: 30554195
author list: Demetri GD
published in: Oncology
information resource reference: Evolution of the International Sarcoma Community: A Personal Perspective. Oncology. 2018; 95 Suppl 1:1-4.
journal title abbreviation: Oncology
publication date: 2018-12-14T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Sarcoma
MeSH DescriptorUI: D012509
MeSH semantic group name: Disorders
number of authors: 637
number of publications: 1854
uniqueness weight: 0.442209
type: Concept

Gastrointestinal Stromal Tumors
MeSH DescriptorUI: D046152
MeSH semantic group name: Disorders
number of authors: 179
number of publications: 638
uniqueness weight: 0.642225
type: Concept

Dean's Office
type: Department
type: Organization

Medicine
type: Department
type: Organization

Pathology
type: Department
type: Organization

Radiology
type: Department
type: Organization

Surgery
type: Department
type: Organization

Oncology
type: Division
type: Organization

Brigham and Women's Hospital
type: Organization

Dana-Farber Cancer Institute
type: Organization

Harvard Medical School
type: Organization

selected publications
maximum weight: 1
minimum weight: 1
number of connections: 431
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/113
predicate: selected publications
type: Network

research areas
maximum weight: 10.966
minimum weight: 0.00150788
number of connections: 823
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/217
predicate: research areas
type: Network

coauthor of
maximum weight: 5.23574
minimum weight: 0.0069486
number of connections: 187
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/363
predicate: coauthor of
type: Network

similar to
maximum weight: 302.961
minimum weight: 38.1494
number of connections: 60
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/494
predicate: similar to
type: Network

George, Suzanne
eCommons Login: SG37
first name: Suzanne
last name: George
full name: Suzanne George, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 23401
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Authorship 135938
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.

Authorship 1155733
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
PubMed Identifier: 31123346
author list: Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA
published in: British journal of cancer
information resource reference: Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Jul; 121(3):281.
journal title abbreviation: Br J Cancer
publication date: 2019-07-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Fisher, David
eCommons Login: DCF4
first name: David
last name: Fisher
full name: David Christopher Fisher, M.D.
has faculty rank: Assistant Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 62220
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Fletcher, Jonathan
eCommons Login: JAF9
first name: Jonathan
last name: Fletcher
full name: Jonathan A. Fletcher, M.D.
has faculty rank: Associate Professor
latitude: 42.33510370000000
longitude: -71.10616490000000
Person ID: 28166
person in primary position: Associate Professor of Pathology
type: Agent
type: Person
preferred title: Associate Professor of Pathology

Van Den Abbeele, Annick
eCommons Login: AV9
first name: Annick
last name: Van Den Abbeele
full name: Annick Diane Van Den Abbeele, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 74701
person in primary position: Professor of Radiology
type: Agent
type: Person
preferred title: Professor of Radiology

Hornick, Jason
eCommons Login: JLH3
first name: Jason
last name: Hornick
full name: Jason L. Hornick, M.D.,Ph.D.
has faculty rank: Full Professor
latitude: 42.33510370000000
longitude: -71.10616490000000
Person ID: 56714
person in primary position: Professor of Pathology
type: Agent
type: Person
preferred title: Professor of Pathology

Choueiri, Toni
eCommons Login: TKC6
first name: Toni
last name: Choueiri
full name: Toni K. Choueiri, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 77491
person in primary position: Jerome and Nancy Kohlberg Professor of Medicine
type: Agent
type: Person
preferred title: Jerome and Nancy Kohlberg Professor of Medicine

Authorship 1159576
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.

Authorship 1159330
type: Authorship
author rank in publication: 20
linked author: Demetri, George
linked information resource: Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
PubMed Identifier: 31173362
author list: Patel S, von Mehren M, Reed DR, Kaiser P, Charlson J, Ryan CW, Rushing D, Livingston M, Singh A, Seth R, Forscher C, D'Amato G, Chawla SP, McCarthy S, Wang G, Parekh T, Knoblauch R, Hensley ML, Maki RG, Demetri GD
published in: Cancer
information resource reference: Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer. 2019 08 01; 125(15):2610-2620.
journal title abbreviation: Cancer
publication date: 2019-06-07T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma.
PubMed Identifier: 31164371
author list: Amin-Mansour A, George S, Sioletic S, Carter SL, Rosenberg M, Taylor-Weiner A, Stewart C, Chevalier A, Seepo S, Tracy A, Getz G, Hornick JL, Nucci MR, Quade B, Demetri GD, Raut CP, Garraway LA, Van Allen EM, Wagner AJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma. Clin Cancer Res. 2019 08 15; 25(16):5135-5142.
journal title abbreviation: Clin Cancer Res
publication date: 2019-06-04T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Raut, Chandrajit
eCommons Login: CPR1
first name: Chandrajit
last name: Raut
full name: Chandrajit P Raut, M.D.
has faculty rank: Full Professor
latitude: 42.33510370000000
longitude: -71.10616490000000
Person ID: 2369
person in primary position: Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology
type: Agent
type: Person
preferred title: Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology

Wagner, Andrew
eCommons Login: AJW2
first name: Andrew
last name: Wagner
full name: Andrew Jay Wagner, M.D., Ph.D.
has faculty rank: Associate Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 42297
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Campos, Susana
eCommons Login: SMC1
first name: Susana
last name: Campos
full name: Susana Maria Campos, M.D.
has faculty rank: Assistant Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 47389
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

McCleary, Nadine
eCommons Login: NAJ3
first name: Nadine
last name: McCleary
full name: Nadine Jackson McCleary, M.D.
has faculty rank: Associate Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 25564
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Lee, Sandra
eCommons Login: SL67
first name: Sandra
last name: Lee
full name: Sandra J. Lee, Sc.D.
has faculty rank: Assistant Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 38425
person in primary position: Assistant Professor of Medicine
type: Agent
type: Person
preferred title: Assistant Professor of Medicine

Authorship 137410
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.

Keskin, Derin
eCommons Login: DBK10
first name: Derin
last name: Keskin
full name: Derin Benerci Keskin, Ph.D.
has faculty rank: Other Faculty
latitude: 42.33789600000000
longitude: -71.10724930000000
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 82351
person in primary position: Research Associate in Medicine
type: Agent
type: Person
preferred title: Research Associate in Medicine

Authorship 128835
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Small molecule tyrosine kinase inhibitor and depression.

Authorship 123830
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.

Authorship 129625
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.

Authorship 1171495
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.

The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours.
PubMed Identifier: 31290566
author list: Lubberman FJE, van der Graaf WTA, Xu L, Cleton A, Demetri GD, Gelderblom H, van Erp NP
published in: British journal of clinical pharmacology
information resource reference: The effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumours. Br J Clin Pharmacol. 2019 10; 85(10):2399-2404.
journal title abbreviation: Br J Clin Pharmacol
publication date: 2019-08-19T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 133736
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.

Authorship 1177008
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.

Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence.
PubMed Identifier: 31371779
author list: Ou WB, Ni N, Zuo R, Zhuang W, Zhu M, Kyriazoglou A, Wu D, Eilers G, Demetri GD, Qiu H, Li B, Marino-Enriquez A, Fletcher JA
published in: Oncogene
information resource reference: Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019 09; 38(39):6615-6629.
journal title abbreviation: Oncogene
publication date: 2019-08-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 148179
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authorship 1186075
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.

Authorship 1183137
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
PubMed Identifier: 31409302
author list: Cesne AL, Bauer S, Demetri GD, Han G, Dezzani L, Ahmad Q, Blay JY, Judson I, Schöffski P, Aglietta M, Hohenberger P, Gelderblom H
published in: BMC cancer
information resource reference: Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. BMC Cancer. 2019 Aug 13; 19(1):794.
journal title abbreviation: BMC Cancer
publication date: 2019-08-13T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors.
PubMed Identifier: 31471313
author list: Serrano C, Leal A, Kuang Y, Morgan JA, Barysauskas CM, Phallen J, Triplett O, Mariño-Enríquez A, Wagner AJ, Demetri GD, Velculescu VE, Paweletz CP, Fletcher JA, George S
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 12 15; 25(24):7287-7293.
journal title abbreviation: Clin Cancer Res
publication date: 2019-08-30T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1191711
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.

Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin.
PubMed Identifier: 31503332
author list: Jones RL, Maki RG, Patel SR, Wang G, McGowan TA, Shalaby WS, Knoblauch RE, von Mehren M, Demetri GD
published in: Cancer
information resource reference: Safety and efficacy of trabectedin when administered in the inpatient versus outpatient setting: Clinical considerations for outpatient administration of trabectedin. Cancer. 2019 Dec 15; 125(24):4435-4441.
journal title abbreviation: Cancer
publication date: 2019-09-10T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 158209
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

Authorship 151618
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Myeloid growth factors clinical practice guidelines in oncology.

Authorship 152912
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

Authorship 1197722
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST.

Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST.
PubMed Identifier: 31618758
author list: Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, Shareef SJ, Javed NM, Raut CP, Eschle BK, Gokhale PC, Hornick JL, Sicinska ET, Demetri GD, Bernstein BE
published in: Nature
information resource reference: Altered chromosomal topology drives oncogenic programs in SDH-deficient GIST. Nature. 2019 Oct 16.
journal title abbreviation: Nature
publication date: 2019-10-16T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1199948
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
PubMed Identifier: 31651363
author list: Ramachandran I, Lowther DE, Dryer-Minnerly R, Wang R, Fayngerts S, Nunez D, Betts G, Bath N, Tipping AJ, Melchiori L, Navenot JM, Glod J, Mackall CL, D'Angelo SP, Araujo DM, Chow WA, Demetri GD, Druta M, Van Tine BA, Grupp SA, Abdul Razak AR, Wilky B, Iyengar M, Trivedi T, Winkle EV, Chagin K, Amado R, Binder GK, Basu S
published in: Journal for immunotherapy of cancer
information resource reference: Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 10 24; 7(1):276.
journal title abbreviation: J Immunother Cancer
publication date: 2019-10-24T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 153418
type: Authorship
author rank in publication: 16
linked author: Demetri, George
linked information resource: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.

Authorship 1200715
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.

Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
PubMed Identifier: 31666694
author list: Flavahan WA, Drier Y, Johnstone SE, Hemming ML, Tarjan DR, Hegazi E, Shareef SJ, Javed NM, Raut CP, Eschle BK, Gokhale PC, Hornick JL, Sicinska ET, Demetri GD, Bernstein BE
published in: Nature
information resource reference: Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs. Nature. 2019 11; 575(7781):229-233.
journal title abbreviation: Nature
publication date: 2019-10-16T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 152668
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.

Authorship 1203163
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.

Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor.
PubMed Identifier: 31703609
author list: Joseph J, Nathenson MJ, Trinh VA, Malik K, Nowell E, Carter K, Weathers SP, Demetri GD, Araujo D, Conley AP
published in: Journal for immunotherapy of cancer
information resource reference: Guillain-Barre syndrome observed with adoptive transfer of lymphocytes genetically engineered with an NY-ESO-1 reactive T-cell receptor. J Immunother Cancer. 2019 11 08; 7(1):296.
journal title abbreviation: J Immunother Cancer
publication date: 2019-11-08T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 115987
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Pathology
is primary position: true
position in department: Pathology
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Pathology
position in organization: Brigham and Women's Hospital

Authorship 122034
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Soft tissue sarcoma clinical practice guidelines in oncology.

Authorship 124022
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass.

Authorship 138037
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Authorship 130347
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.

Authorship 147665
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

Authorship 1210869
type: Authorship
author rank in publication: 38
linked author: Demetri, George
linked information resource: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
PubMed Identifier: 31838007
author list: Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD
published in: The Lancet. Oncology
information resource reference: Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282.
journal title abbreviation: Lancet Oncol
publication date: 2019-12-11T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 132116
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation.

Authorship 1215116
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.

A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
PubMed Identifier: 31896519
author list: Cote GM, Choy E, Chen T, Marino-Enriquez A, Morgan J, Merriam P, Thornton K, Wagner AJ, Nathenson MJ, Demetri G, George S
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32.
journal title abbreviation: Eur J Cancer
publication date: 2019-12-31T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1223112
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.

Authorship 1223488
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

Authorship 1223464
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.
PubMed Identifier: 32018433
author list: Penel N, Demetri GD, Blay JY, Cousin S, Maki RG, Chawla SP, Judson I, von Mehren M, Schöffski P, Verweij J, Casali P, Rodenhuis S, Schütte HJ, Cassar A, Gomez J, Nieto A, Zintl P, Pontes MJ, Le Cesne A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. Ann Oncol. 2013 Feb; 24(2):537-542.
journal title abbreviation: Ann Oncol
publication date: 2019-12-04T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
PubMed Identifier: 32018675
author list: Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, Blay JY
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012 Mar; 23(3):771-776.
journal title abbreviation: Ann Oncol
publication date: 2019-12-04T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
PubMed Identifier: 32018827
author list: George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012 Dec; 23(12):3180-3187.
journal title abbreviation: Ann Oncol
publication date: 2019-12-04T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1225887
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.

Authorship 1226220
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001).

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.
PubMed Identifier: 32042194
author list: Painter CA, Jain E, Tomson BN, Dunphy M, Stoddard RE, Thomas BS, Damon AL, Shah S, Kim D, Gómez Tejeda Zañudo J, Hornick JL, Chen YL, Merriam P, Raut CP, Demetri GD, Van Tine BA, Lander ES, Golub TR, Wagle N
published in: Nature medicine
information resource reference: The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020 02; 26(2):181-187.
journal title abbreviation: Nat Med
publication date: 2020-02-10T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001).
PubMed Identifier: 32085042
author list: Siena S, Demetri G, Doebele R, Chae Y, Conkling P, Garrido-Laguna I, Garrido P, Rolfo C, Sigal D, Eng S, Simmons B, Ye C, Ciardiello F
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001). Ann Oncol. 2019 Jul; 30 Suppl 4:iv134.
journal title abbreviation: Ann Oncol
publication date: 2019-12-04T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1.
PubMed Identifier: 32133433
author list: Hemming ML, Nathenson MJ, Lin JR, Mei S, Du Z, Malik K, Marino-Enriquez A, Jagannathan JP, Sorger PK, Bertagnolli M, Sicinska E, Demetri GD, Santagata S
published in: JCO precision oncology
information resource reference: Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1. JCO Precis Oncol. 2020; 4:79-90.
journal title abbreviation: JCO Precis Oncol
publication date: 2020-02-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1231649
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

Authorship 1233016
type: Authorship
author rank in publication: 12
linked author: Demetri, George
linked information resource: Response and mechanisms of resistance to larotrectinib and selitrectinib in metastatic undifferentiated sarcoma harboring oncogenic fusion of NTRK1.

Authorship 1231916
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.

Authorship 1234192
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Activity of larotrectinib in patients with TRK fusion GI malignancies.

Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers.
PubMed Identifier: 32129093
author list: Farago AF, Demetri GD
published in: Future oncology (London, England)
information resource reference: Larotrectinib, a selective tropomyosin receptor kinase inhibitor for adult and pediatric tropomyosin receptor kinase fusion cancers. Future Oncol. 2020 Mar; 16(9):417-425.
journal title abbreviation: Future Oncol
publication date: 2020-03-04T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.
PubMed Identifier: 32131246
author list: Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, Ye C, Simmons B, Demetri GD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2019 Apr; 30 Suppl 2:ii48-ii49.
journal title abbreviation: Ann Oncol
publication date: 2019-04-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Activity of larotrectinib in patients with TRK fusion GI malignancies.
PubMed Identifier: 32176998
author list: Nathenson M, Demetri G, Lassen U, Hong D, Boni V, Deeken J, Dowlati A, Cox M, Ku N, Cruickshank S, Qamoos H, Drilon A
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Activity of larotrectinib in patients with TRK fusion GI malignancies. Ann Oncol. 2018 Jun; 29 Suppl 5:v107.
journal title abbreviation: Ann Oncol
publication date: 2020-01-07T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1235580
type: Authorship
author rank in publication: 12
linked author: Demetri, George
linked information resource: LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.

LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications.
PubMed Identifier: 32210091
author list: Ben-Ami E, Perret R, Huang Y, Courgeon F, Gokhale PC, Laroche-Clary A, Eschle BK, Velasco V, Le Loarer F, Algeo MP, Purcell J, Demetri GD, Italiano A
published in: Cancers
information resource reference: LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications. Cancers (Basel). 2020 Mar 23; 12(3).
journal title abbreviation: Cancers (Basel)
publication date: 2020-03-23T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 126921
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN sarcoma practice guidelines. National Comprehensive Cancer Network.

Authorship 17093
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1064581

Authorship 1243984
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments.

The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments.
PubMed Identifier: 32349562
author list: Blay JY, Le Cesne A, Demetri GD
published in: Expert review of anticancer therapy
information resource reference: The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. Expert Rev Anticancer Ther. 2020 04; 20(sup1):29-39.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2020-04-29T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 178140
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN: New applications for erythropoietin.

Authorship 191042
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.

Authorship 1257030
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.

Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.
PubMed Identifier: 32518213
author list: Hemming ML, Fan C, Raut CP, Demetri GD, Armstrong SA, Sicinska E, George S
published in: Molecular cancer research : MCR
information resource reference: Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes. Mol Cancer Res. 2020 09; 18(9):1302-1314.
journal title abbreviation: Mol Cancer Res
publication date: 2020-06-09T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 148127
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.

Authorship 139449
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.

Authorship 210258
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

Authorship 157912
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.

Authorship 199080
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

Authorship 219192
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.

Authorship 195192
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.

Authorship 136736
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.

Authorship 1284437
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.

Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network.
PubMed Identifier: 32891793
author list: Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, Dei Tos AP, Desai J, Fletcher JA, Gelderblom H, George S, Gronchi A, Haas RL, Hindi N, Hohenberger P, Joensuu H, Jones RL, Judson I, Kang YK, Kawai A, Lazar AJ, Le Cesne A, Maestro R, Maki RG, Martín J, Patel S, Penault-Llorca F, Premanand Raut C, Rutkowski P, Safwat A, Sbaraglia M, Schaefer IM, Shen L, Serrano C, Schöffski P, Stacchiotti S, Sundby Hall K, Tap WD, Thomas DM, Trent J, Valverde C, van der Graaf WTA, von Mehren M, Wagner A, Wardelmann E, Naito Y, Zalcberg J, Blay JY
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020 11; 31(11):1506-1517.
journal title abbreviation: Ann Oncol
publication date: 2020-09-03T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 188722
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Authorship 1293477
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.

Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
PubMed Identifier: 33035459
author list: Gounder M, Schöffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S
published in: The Lancet. Oncology
information resource reference: Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol. 2020 11; 21(11):1423-1432.
journal title abbreviation: Lancet Oncol
publication date: 2020-10-06T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 231392
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.

Authorship 1308000
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.

FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs.
PubMed Identifier: 33257426
author list: Kluetz PG, Keegan P, Demetri GD, Thornton K, Sul J, Kim J, Katzen H, Burke LB, Harvey RD, Alebachew E, Agrawal S, Nair A, Donoghue M, Pierce WF, Shord SS, Gao JJ, Pazdur R
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: FDA Oncology Center of Excellence Project Renewal: Engaging the Oncology Community to Update Product Labeling for Older Oncology Drugs. Clin Cancer Res. 2021 02 15; 27(4):916-921.
journal title abbreviation: Clin Cancer Res
publication date: 2020-11-30T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
PubMed Identifier: 33296083
author list: Gounder MM, Merriam P, Ratan R, Patel SR, Chugh R, Villalobos VM, Thornton M, Van Tine BA, Abdelhamid AH, Whalen J, Yang J, Rajarethinam A, Duh MS, Bobbili PJ, Huynh L, Totev TI, Lax AK, Agarwal S, Demetri GD
published in: Cancer
information resource reference: Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma. Cancer. 2021 04 15; 127(8):1311-1317.
journal title abbreviation: Cancer
publication date: 2020-12-09T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1313473
type: Authorship
author rank in publication: 19
linked author: Demetri, George
linked information resource: Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.

Authorship 1316313
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.
PubMed Identifier: 33414136
author list: Singh H, Li YY, Spurr LF, Shinagare AB, Abhyankar R, Reilly E, Brais LK, Nag A, Ducar MD, Thorner AR, Shapiro GI, Keller RB, Siletti C, Clark JW, Farago AF, Lin JJ, Demetri GD, Gujrathi R, Kulke MH, MacConaill LE, Ligon AH, Sicinska E, Meyerson ML, Meyerhardt JA, Cherniack AD, Wolpin BM, Ng K, Giannakis M, Hornick JL, Cleary JM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions. Clin Cancer Res. 2021 03 15; 27(6):1695-1705.
journal title abbreviation: Clin Cancer Res
publication date: 2021-01-07T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1320805
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor.

HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor.
PubMed Identifier: 33451979
author list: Hemming ML, Coy S, Lin JR, Andersen JL, Przybyl J, Mazzola E, Abdelhamid Ahmed AH, van de Rijn M, Sorger PK, Armstrong SA, Demetri GD, Santagata S
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: HAND1 and BARX1 Act as Transcriptional and Anatomic Determinants of Malignancy in Gastrointestinal Stromal Tumor. Clin Cancer Res. 2021 03 15; 27(6):1706-1719.
journal title abbreviation: Clin Cancer Res
publication date: 2021-01-15T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1328172
type: Authorship
author rank in publication: 23
linked author: Demetri, George
linked information resource: Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.

Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate.
PubMed Identifier: 33579785
author list: Iida K, Abdelhamid Ahmed AH, Nagatsuma AK, Shibutani T, Yasuda S, Kitamura M, Hattori C, Abe M, Hasegawa J, Iguchi T, Karibe T, Nakada T, Inaki K, Kamei R, Abe Y, Nomura T, Andersen JL, Santagata S, Hemming ML, George S, Doi T, Ochiai A, Demetri GD, Agatsuma T
published in: Cancer discovery
information resource reference: Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Cancer Discov. 2021 06; 11(6):1508-1523.
journal title abbreviation: Cancer Discov
publication date: 2021-02-12T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1344477
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.

First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors.
PubMed Identifier: 33820780
author list: Demetri GD, Luke JJ, Hollebecque A, Powderly JD, Spira AI, Subbiah V, Naumovski L, Chen C, Fang H, Lai DW, Yue H, Polepally AR, Purcell JW, Robinson R, Sharma P, Allison JP, Tolcher A, Villalobos VM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 07 01; 27(13):3556-3566.
journal title abbreviation: Clin Cancer Res
publication date: 2021-04-05T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1351101
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.

Authorship 1346831
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas.

Authorship 1349645
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Real-World Evidence and Advanced Soft Tissue Sarcoma: An Unbreakable Bond (ESMO Sarcoma and GIST Symposium 2020 Industry Satellite Symposium, Milan, February 4, 2020).

Authorship 1349800
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.

Real-World Evidence and Advanced Soft Tissue Sarcoma: An Unbreakable Bond (ESMO Sarcoma and GIST Symposium 2020 Industry Satellite Symposium, Milan, February 4, 2020).
PubMed Identifier: 33853079
author list: Demetri GD
published in: Oncology
information resource reference: Real-World Evidence and Advanced Soft Tissue Sarcoma: An Unbreakable Bond (ESMO Sarcoma and GIST Symposium 2020 Industry Satellite Symposium, Milan, February 4, 2020). Oncology. 2021; 99 Suppl 1:1-2.
journal title abbreviation: Oncology
publication date: 2021-04-14T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas.
PubMed Identifier: 33853076
author list: Demetri GD, Stacchiotti S
published in: Oncology
information resource reference: Contributions of Real-World Evidence and Real-World Data to Decision-Making in the Management of Soft Tissue Sarcomas. Oncology. 2021; 99 Suppl 1:3-7.
journal title abbreviation: Oncology
publication date: 2021-04-14T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities.
PubMed Identifier: 33910263
author list: Stacchiotti S, Frezza AM, Blay JY, Baldini EH, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, Chiang RC, Demetri GD, Demicco EG, Desai J, Eriksson M, Gelderblom H, George S, Gounder MM, Gronchi A, Gupta A, Haas RL, Hayes-Jardon A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Lim J, Chirlaque López MD, Maestro R, Marcos-Gragera R, Martin Broto J, Matsuda T, Mir O, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Sundby Hall K, Tap WD, Thomas DM, van der Graaf WTA, van Houdt WJ, Visser O, von Mehren M, Wagner AJ, Wilky BA, Won YJ, Fletcher CDM, Dei Tos AP, Trama A
published in: Cancer
information resource reference: Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. Cancer. 2021 08 15; 127(16):2934-2942.
journal title abbreviation: Cancer
publication date: 2021-04-28T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours.
PubMed Identifier: 33930659
author list: Paz-Ares L, Barlesi F, Siena S, Ahn MJ, Drilon A, Conley A, Rolfo C, Wolf J, Seto T, Doebele R, Kapre A, Chen D, McCallum S, Osborne S, Demetri G
published in: ESMO open
information resource reference: Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open. 2021 06; 6(3):100113.
journal title abbreviation: ESMO Open
publication date: 2021-04-27T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1352707
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.

Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
PubMed Identifier: 33960681
author list: Jones RL, Herzog TJ, Patel SR, von Mehren M, Schuetze SM, Van Tine BA, Coleman RL, Knoblauch R, Triantos S, Hu P, Shalaby W, McGowan T, Monk BJ, Demetri GD
published in: Cancer medicine
information resource reference: Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer. Cancer Med. 2021 06; 10(11):3565-3574.
journal title abbreviation: Cancer Med
publication date: 2021-05-07T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1365019
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.

Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
PubMed Identifier: 34140638
author list: Bauer S, Demetri GD, Halilovic E, Dummer R, Meille C, Tan DSW, Guerreiro N, Jullion A, Ferretti S, Jeay S, Van Bree L, Hourcade-Potelleret F, Wuerthner JU, Fabre C, Cassier PA
published in: British journal of cancer
information resource reference: Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies. Br J Cancer. 2021 08; 125(5):687-698.
journal title abbreviation: Br J Cancer
publication date: 2021-06-17T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 183626
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Expression of a novel 3.5-kb macrophage colony-stimulating factor transcript in human myeloma cells.

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1378168
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types.

Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types.
PubMed Identifier: 34285574
author list: Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D
published in: Cancer management and research
information resource reference: Effect of Regorafenib in Delaying Definitive Deterioration in Health-Related Quality of Life in Patients with Advanced Cancer of Three Different Tumor Types. Cancer Manag Res. 2021; 13:5523-5533.
journal title abbreviation: Cancer Manag Res
publication date: 2021-07-12T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 170509
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/869089

Authorship 1400963
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.

E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor.
PubMed Identifier: 34621020
author list: García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, Arribas J, Serrano C
published in: Oncogene
information resource reference: E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. Oncogene. 2021 12; 40(48):6614-6626.
journal title abbreviation: Oncogene
publication date: 2021-10-07T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 186783
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: ET-743: the US experience in sarcomas of soft tissues.

Authorship 1404652
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020.
PubMed Identifier: 34667027
author list: Arondekar B, Duh MS, Bhak RH, DerSarkissian M, Huynh L, Wang K, Wojciehowski J, Wu M, Wornson B, Niyazov A, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015-2020. Clin Cancer Res. 2022 01 01; 28(1):27-35.
journal title abbreviation: Clin Cancer Res
publication date: 2021-10-19T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 218826
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma.

Authorship 163821
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma.

Authorship 231315
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
PubMed Identifier: 35144967
author list: Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022 04 01; 28(7):1302-1312.
journal title abbreviation: Clin Cancer Res
publication date: 2022-04-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1431741
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.

Authorship 1439455
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.

Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression.
PubMed Identifier: 35325095
author list: Hemming ML, Bhola P, Loycano MA, Anderson JA, Taddei ML, Doyle LA, Lavrova E, Andersen JL, Klega KS, Benson MR, Crompton BD, Raut CP, George S, Letai A, Demetri GD, Sicinska E
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clin Cancer Res. 2022 06 01; 28(11):2397-2408.
journal title abbreviation: Clin Cancer Res
publication date: 2022-06-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Research Associate in Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Research Associate in Medicine
position in organization: Dana-Farber Cancer Institute

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.
PubMed Identifier: 35553647
author list: Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. Clin Cancer Res. 2022 May 13; 28(10):2196.
journal title abbreviation: Clin Cancer Res
publication date: 2022-05-13T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1451704
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors.

Authorship 335180
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Molecular basis for sunitinib efficacy and future clinical development.

Authorship 337720
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Myeloid growth factors. Clinical practice guidelines in oncology.

Assistant Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Assistant Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1458291
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Derivation and validation of a risk classification tree for patients with synovial sarcoma.

Derivation and validation of a risk classification tree for patients with synovial sarcoma.
PubMed Identifier: 35670308
author list: Neel DV, Ma C, Collins NB, Hornick JL, Demetri GD, Shulman DS
published in: Cancer medicine
information resource reference: Derivation and validation of a risk classification tree for patients with synovial sarcoma. Cancer Med. 2023 01; 12(1):170-178.
journal title abbreviation: Cancer Med
publication date: 2022-06-07T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 163477
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.

Professor of Radiology
is primary position: true
position in department: Radiology
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Professor of Radiology
position in organization: Brigham and Women's Hospital

Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.
PubMed Identifier: 36175617
author list: Schaefer IM, Hemming ML, Lundberg MZ, Serrata MP, Goldaracena I, Liu N, Yin P, Paulo JA, Gygi SP, George S, Morgan JA, Bertagnolli MM, Sicinska ET, Chu C, Zheng S, Mariño-Enríquez A, Hornick JL, Raut CP, Ou WB, Demetri GD, Saka SK, Fletcher JA
published in: British journal of cancer
information resource reference: Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST. Br J Cancer. 2022 11; 127(11):2072-2085.
journal title abbreviation: Br J Cancer
publication date: 2022-09-29T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1498814
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.

Authorship 1497295
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/203401728

Authorship 1500994
type: Authorship
author rank in publication: 20
linked author: Demetri, George
linked information resource: Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.

Authorship 1491673
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.

Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors.
PubMed Identifier: 35939431
author list: Hibar DP, Demetri GD, Peters S, Davies J, Humblet O, Maund SL, Perez L
published in: PloS one
information resource reference: Real-world survival outcomes in patients with locally advanced or metastatic NTRK fusion-positive solid tumors receiving standard-of-care therapies other than targeted TRK inhibitors. PLoS One. 2022; 17(8):e0270571.
journal title abbreviation: PLoS One
publication date: 2022-08-08T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/203401728
PubMed Identifier: 36031697
author list: Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ
published in: Cancer treatment reviews
information resource reference: Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. Cancer Treat Rev. 2022 Nov; 110:102455.
journal title abbreviation: Cancer Treat Rev
publication date: 2022-08-18T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments.

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma.
PubMed Identifier: 36075914
author list: Gyurdieva A, Zajic S, Chang YF, Houseman EA, Zhong S, Kim J, Nathenson M, Faitg T, Woessner M, Turner DC, Hasan AN, Glod J, Kaplan RN, D'Angelo SP, Araujo DM, Chow WA, Druta M, Demetri GD, Van Tine BA, Grupp SA, Fine GD, Eleftheriadou I
published in: Nature communications
information resource reference: Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma. Nat Commun. 2022 09 08; 13(1):5296.
journal title abbreviation: Nat Commun
publication date: 2022-09-08T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 177722
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.

Authorship 19333
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/899913

Authorship 1570734
type: Authorship
author rank in publication: 12
linked author: Demetri, George
linked information resource: Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma.

Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma.
PubMed Identifier: 37492096
author list: Bevill SM, Casaní-Galdón S, El Farran CA, Cytrynbaum EG, Macias KA, Oldeman SE, Oliveira KJ, Moore MM, Hegazi E, Adriaens C, Najm FJ, Demetri GD, Cohen S, Mullen JT, Riggi N, Johnstone SE, Bernstein BE
published in: Cell genomics
information resource reference: Impact of supraphysiologic MDM2 expression on chromatin networks and therapeutic responses in sarcoma. Cell Genom. 2023 Jul 12; 3(7):100321.
journal title abbreviation: Cell Genom
publication date: 2023-05-11T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1586096
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.

Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
PubMed Identifier: 37769113
author list: Kummar S, Shen L, Hong DS, McDermott R, Keedy VL, Casanova M, Demetri GD, Dowlati A, Melcón SG, Lassen UN, Leyvraz S, Liu T, Moreno V, Patel J, Patil T, Mallick AB, Sousa N, Tahara M, Ziegler DS, Norenberg R, Arvis P, Brega N, Drilon A, Tan DSW
published in: Cancer
information resource reference: Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas. Cancer. 2023 12 01; 129(23):3772-3782.
journal title abbreviation: Cancer
publication date: 2023-09-28T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1601475
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
PubMed Identifier: 37890277
author list: Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CDM, Silberman S, Dimitrijevic S, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. J Clin Oncol. 2023 11 01; 41(31):4829-4836.
journal title abbreviation: J Clin Oncol
publication date: 2023-11-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 177418
type: Authorship
author rank in publication: 20
linked author: Demetri, George
linked information resource: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authorship 181154
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.

Authorship 184271
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Myelosuppression and "conventional" chemotherapy: what price, what benefit?

Authorship 482632
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.

Authorship 491787
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Authorship 52946
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.

Authorship 556431
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.

Authorship 224348
type: Authorship
author rank in publication: 13
linked author: Demetri, George
linked information resource: A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.

Authorship 1640057
type: Authorship
author rank in publication: 30
linked author: Demetri, George
linked information resource: Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.

Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.
PubMed Identifier: 38510282
author list: Nassar AH, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Bou Farhat E, Williams JM, Collins JD, Al-Hader A, McKay RR, Malvar C, Sabra M, Zhong C, El Alam R, Chehab O, Lima J, Phan M, Dalla Pria HF, Trevino A, Neilan TG, Kwan JM, Ravi V, Deshpande H, Demetri G, Choueiri TK, Naqash AR
published in: JACC. CardioOncology
information resource reference: Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study. JACC CardioOncol. 2024 Feb; 6(1):71-79.
journal title abbreviation: JACC CardioOncol
publication date: 2024-01-16T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1642420
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.

Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
PubMed Identifier: 38554725
author list: D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA
published in: Lancet (London, England)
information resource reference: Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial. Lancet. 2024 04 13; 403(10435):1460-1471.
journal title abbreviation: Lancet
publication date: 2024-03-27T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 171593
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.
PubMed Identifier: 38723278
author list: Cote GM, Haddox CL, Choy E, Merriam PA, Mazzola E, Venkataraman V, Alcindor T, Wagner AJ, Demetri GD, George S
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma. Clin Cancer Res. 2024 Jul 01; 30(13):2702-2708.
journal title abbreviation: Clin Cancer Res
publication date: 2024-07-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 233594
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Soft tissue sarcoma.

Authorship 249359
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.

Authorship 253091
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Management of soft-tissue sarcomas: an overview and update.

Authorship 1647437
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue Sarcoma.

Authorship 348495
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.

Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology
is primary position: true
position in department: Surgery
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology
position in organization: Brigham and Women's Hospital

Authorship 400040
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors.

Authorship 406160
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Two patients with sarcoma. Case 2. Uterine sarcoma.

Authorship 407530
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Myeloid growth factors.

Authorship 246811
type: Authorship
author rank in publication: 13
linked author: Demetri, George
linked information resource: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

Authorship 1668321
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Improving Collection and Analysis of Overall Survival Data.

Improving Collection and Analysis of Overall Survival Data.
PubMed Identifier: 39037364
author list: Rodriguez LR, Gormley NJ, Lu R, Amatya AK, Demetri GD, Flaherty KT, Mesa RA, Pazdur R, Sekeres MA, Shan M, Snapinn S, Theoret MR, Umoja R, Vallejo J, Warren NJH, Xu Q, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Improving Collection and Analysis of Overall Survival Data. Clin Cancer Res. 2024 Sep 13; 30(18):3974-3982.
journal title abbreviation: Clin Cancer Res
publication date: 2024-09-13T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Associate Professor of Pathology
is primary position: true
position in department: Pathology
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 1
type: Position
HR job title: Associate Professor of Pathology
position in organization: Brigham and Women's Hospital

Jerome and Nancy Kohlberg Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Jerome and Nancy Kohlberg Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 272259
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations.

Authorship 665156
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.

Authorship 647861
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.

Authorship 665477
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/25892806

Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy.
PubMed Identifier: 23714727
author list: Zhang YX, van Oosterwijk JG, Sicinska E, Moss S, Remillard SP, van Wezel T, Bühnemann C, Hassan AB, Demetri GD, Bovée JV, Wagner AJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res. 2013 Jul 15; 19(14):3796-807.
journal title abbreviation: Clin Cancer Res
publication date: 2013-05-28T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/25892806
PubMed Identifier: 23715582
author list: Demetri GD, Chawla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui-Nguyen B, Cranmer LD, Reichardt P, Bompas E, Alcindor T, Rushing D, Song Y, Lee RM, Ebbinghaus S, Eid JE, Loewy JW, Haluska FG, Dodion PF, Blay JY
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013 Jul 01; 31(19):2485-92.
journal title abbreviation: J Clin Oncol
publication date: 2013-05-28T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study.
PubMed Identifier: 23385197
author list: Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, Schuetze S, Li J, Aymes A, Demetri GD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013 Jun; 24(6):1703-9.
journal title abbreviation: Ann Oncol
publication date: 2013-02-05T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 7556
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Authorship 187800
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).

Authorship 205091
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.

Authorship 56821
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.

Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
PubMed Identifier: 23775962
author list: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013 Sep 10; 31(26):3182-90.
journal title abbreviation: J Clin Oncol
publication date: 2013-06-17T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.
PubMed Identifier: 23584476
author list: Mariño-Enríquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA
published in: Oncogene
information resource reference: Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors. Oncogene. 2014 Apr 03; 33(14):1872-6.
journal title abbreviation: Oncogene
publication date: 2013-04-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 679083
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.

Authorship 679979
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.

Authorship 679403
type: Authorship
author rank in publication: 23
linked author: Demetri, George
linked information resource: Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials.
PubMed Identifier: 24022187
author list: Cesne AL, Judson I, Maki R, Grosso F, Schuetze S, Mehren MV, Chawla SP, Demetri GD, Nieto A, Tanovic A, Blay JY
published in: British journal of cancer
information resource reference: Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. Br J Cancer. 2013 Oct 01; 109(7):1717-24.
journal title abbreviation: Br J Cancer
publication date: 2013-09-10T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
PubMed Identifier: 23860199
author list: DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K
published in: Annals of surgery
information resource reference: Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013 Sep; 258(3):422-9.
journal title abbreviation: Ann Surg
publication date: 2013-09-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 291058
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.

Authorship 689119
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
PubMed Identifier: 24140183
author list: Kang YK, Ryu MH, Yoo C, Ryoo BY, Kim HJ, Lee JJ, Nam BH, Ramaiya N, Jagannathan J, Demetri GD
published in: The Lancet. Oncology
information resource reference: Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2013 Nov; 14(12):1175-82.
journal title abbreviation: Lancet Oncol
publication date: 2013-10-18T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 337967
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes.

Authorship 1733600
type: Authorship
author rank in publication: 21
linked author: Demetri, George
linked information resource: Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Authorship 1734625
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.

SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
PubMed Identifier: 39932221
author list: Cote GM, Chawla SP, Demetri G, Kasper B, Jones RL, Broto JM, Wooley J, Weiss MC, Tafuto S, Badalamenti G, Carrasco I, Peinado P, Blay JY, Boggio G, Fernandez C, Nieto A, Kahatt C, Alfaro V, Le Cesne A
published in: Future oncology (London, England)
information resource reference: SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma. Future Oncol. 2025 Apr; 21(8):943-951.
journal title abbreviation: Future Oncol
publication date: 2025-02-11T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.
PubMed Identifier: 39896505
author list: Pimenta EM, Garza AE, Camp SY, Park J, Hoffman SE, Valderrábano L, Fu J, Bi K, Karam J, Titchen BM, Khandekar MJ, Shannon E, Kang YJ, Nag A, Thorner AR, Raut CP, Hornick JL, Merriam P, Solimini NL, George S, Demetri GD, Van Allen EM
published in: bioRxiv : the preprint server for biology
information resource reference: Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. bioRxiv. 2025 Jan 24.
journal title abbreviation: bioRxiv
publication date: 2025-01-24T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 350091
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: PDGFRA activating mutations in gastrointestinal stromal tumors.

Authorship 693140
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
PubMed Identifier: 24045182
author list: Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas. Clin Cancer Res. 2013 Nov 01; 19(21):6020-9.
journal title abbreviation: Clin Cancer Res
publication date: 2013-09-17T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 22596
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1052797

Authorship 361378
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.

Authorship 367136
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/903562

Authorship 698986
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
PubMed Identifier: 24356634
author list: Ganjoo KN, Villalobos VM, Kamaya A, Fisher GA, Butrynski JE, Morgan JA, Wagner AJ, D'Adamo D, McMillan A, Demetri GD, George S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2014 Jan; 25(1):236-40.
journal title abbreviation: Ann Oncol
publication date: 2014-01-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 229803
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Aberrant AKT activation drives well-differentiated liposarcoma.

Authorship 25275
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.

Authorship 398652
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature.

Authorship 285037
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.

Authorship 264576
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Co-Fund Director of the Bertarelli Rare Cancer Fund (BCRF)
position in department: Dean's Office
position in division: https://connects.catalyst.harvard.edu/Profiles/profile/1229413
sort order: 2
type: Position
HR job title: Co-Fund Director of the Bertarelli Rare Cancer Fund (BCRF)
position in organization: Harvard Medical School

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 300259
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).

Authorship 314692
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

Authorship 475528
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: The evolution of a revolutionary class: extending benefits of tyrosine kinase inhibitors--introduction.

Authorship 714890
type: Authorship
author rank in publication: 12
linked author: Demetri, George
linked information resource: Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.

Authorship 715521
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.

Authorship 721847
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.

Authorship 717122
type: Authorship
author rank in publication: 13
linked author: Demetri, George
linked information resource: Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.

Authorship 723658
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: International expert opinion on patient-tailored management of soft tissue sarcomas.

Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
PubMed Identifier: 24388774
author list: Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014 Mar; 50(5):981-6.
journal title abbreviation: Eur J Cancer
publication date: 2014-01-02T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

International expert opinion on patient-tailored management of soft tissue sarcomas.
PubMed Identifier: 24295638
author list: Blay JY, Sleijfer S, Schöffski P, Kawai A, Brodowicz T, Demetri GD, Maki RG
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: International expert opinion on patient-tailored management of soft tissue sarcomas. Eur J Cancer. 2014 Mar; 50(4):679-89.
journal title abbreviation: Eur J Cancer
publication date: 2013-11-29T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors.
PubMed Identifier: 24555070
author list: Tomasetti C, Demetri GD, Parmigiani G
published in: F1000Research
information resource reference: Why tyrosine kinase inhibitor resistance is common in advanced gastrointestinal stromal tumors. F1000Res. 2013; 2:152.
journal title abbreviation: F1000Res
publication date: 2013-07-09T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 339831
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.

Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
PubMed Identifier: 24222211
author list: George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C
published in: Cancer
information resource reference: Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer. 2014 Mar 01; 120(5):738-43.
journal title abbreviation: Cancer
publication date: 2013-11-12T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 224880
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.

Authorship 322396
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes.

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 285199
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.

Authorship 290271
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.

Authorship 29920
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Major developments in the understanding and treatment of soft-tissue sarcomas in adults.

Authorship 29942
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.

Authorship 210458
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
PubMed Identifier: 24687822
author list: Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation. J Clin Oncol. 2015 Aug 01; 33(22):e93-6.
journal title abbreviation: J Clin Oncol
publication date: 2014-03-31T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 731127
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
PubMed Identifier: 24638003
author list: Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014 May 20; 32(15):1563-70.
journal title abbreviation: J Clin Oncol
publication date: 2014-03-17T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 732834
type: Authorship
author rank in publication: 16
linked author: Demetri, George
linked information resource: Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Dystrophin is a tumor suppressor in human cancers with myogenic programs.
PubMed Identifier: 24793134
author list: Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA
published in: Nature genetics
information resource reference: Dystrophin is a tumor suppressor in human cancers with myogenic programs. Nat Genet. 2014 Jun; 46(6):601-6.
journal title abbreviation: Nat Genet
publication date: 2014-05-04T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 734197
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: A new model: physician-patient collaboration in online communities and the clinical practice of oncology.

Authorship 734736
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/32105799

A new model: physician-patient collaboration in online communities and the clinical practice of oncology.
PubMed Identifier: 24451778
author list: West HJ, Debronkart D, Demetri GD
published in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
information resource reference: A new model: physician-patient collaboration in online communities and the clinical practice of oncology. Am Soc Clin Oncol Educ Book. 2012; 443-8.
journal title abbreviation: Am Soc Clin Oncol Educ Book
publication date: 2012-01-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/32105799
PubMed Identifier: 24451812
author list: Sleijfer S, Judson I, Demetri GD
published in: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
information resource reference: How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and data. Am Soc Clin Oncol Educ Book. 2012; 645-50.
journal title abbreviation: Am Soc Clin Oncol Educ Book
publication date: 2012-01-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: How to decide whether to offer and use "nonstandard" therapies in patients with advanced sarcomas and gastrointestinal stromal tumors: global variations in clinical practice, assessment, and access to therapies in diseases with limited incidence and data.

Authorship 1794799
type: Authorship
author rank in publication: 16
linked author: Demetri, George
linked information resource: A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE).

Authorship 1824520
type: Authorship
author rank in publication: 16
linked author: Demetri, George
linked information resource: Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors.

Authorship 1851976
type: Authorship
author rank in publication: 27
linked author: Demetri, George
linked information resource: Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors.
PubMed Identifier: 40596693
author list: Abraham J, Domenyuk V, Perdigones N, Klimov S, Antani S, Yoshino T, Heath EI, Lou E, Liu SV, Marshall JL, El-Deiry WS, Shields AF, Dietrich MF, Nakamura Y, Fujisawa T, Demetri GD, Barker A, Xiu J, Sacchetti DA, Stahl S, Hahn-Lowry R, Stark A, Swensen J, Poste G, Halbert DD, Oberley M, Radovich M, Sledge GW, Spetzler DB
published in: Scientific reports
information resource reference: Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors. Sci Rep. 2025 Jul 01; 15(1):21173.
journal title abbreviation: Sci Rep
publication date: 2025-07-01T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.
PubMed Identifier: 41564157
author list: Pimenta EM, Garza AE, Camp SY, Park J, Hoffman SE, Valderrábano L, Fu J, Bi K, Carson MT, Karam J, Titchen BM, Medjahed S, Khandekar MJ, Shannon E, Kang YJ, Coy S, Lin JR, Nag A, Thorner AR, Gibson WJ, Santagata S, Raut CP, Hornick JL, Merriam P, Solimini NL, George S, Demetri GD, Van Allen EM
published in: Science translational medicine
information resource reference: Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. Sci Transl Med. 2026 Jan 21; 18(833):eadw4689.
journal title abbreviation: Sci Transl Med
publication date: 2026-01-21T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE).
PubMed Identifier: 41481257
author list: Cote GM, Aberoumand M, Choy E, Sebastian L, Mazzola E, Grimison P, Merriam P, Ballinger M, Thavaneswaran S, Lin F, Grady JP, Millward M, Brown MP, Harrup R, Espinoza D, Demetri G, Littlefield BA, Simes RJ, George S, Thomas D
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE). Clin Cancer Res. 2026 Jan 02.
journal title abbreviation: Clin Cancer Res
publication date: 2026-01-02T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 338770
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Leiomyosarcoma of the inferior vena cava: survival after aggressive management.

Authorship 742778
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/32699702

Authorship 744547
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

https://connects.catalyst.harvard.edu/Profiles/profile/32699702
PubMed Identifier: 24930624
author list: Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, Motzer RJ
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 2014 Aug; 50(12):2162-70.
journal title abbreviation: Eur J Cancer
publication date: 2014-06-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.
PubMed Identifier: 24821824
author list: Grothey A, George S, van Cutsem E, Blay JY, Sobrero A, Demetri GD
published in: The oncologist
information resource reference: Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014 Jun; 19(6):669-80.
journal title abbreviation: Oncologist
publication date: 2014-05-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 395774
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.

Authorship 402587
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Authorship 438534
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.

Authorship 323312
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.

Authorship 327080
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.

Authorship 305915
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.

Authorship 309127
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.

Authorship 316619
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.

Authorship 364033
type: Authorship
author rank in publication: 13
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/856270

Authorship 376336
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Granulocyte colony-stimulating factor and its receptor.

Authorship 398687
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Pharmacologic treatment options in patients with thrombocytopenia.

Authorship 747559
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.
PubMed Identifier: 25102852
author list: de Wit D, van Erp NP, Khosravan R, Wiltshire R, Allred R, Demetri GD, Guchelaar HJ, Gelderblom H
published in: BMC cancer
information resource reference: Effect of gastrointestinal resection on sunitinib exposure in patients with GIST. BMC Cancer. 2014 Aug 08; 14:575.
journal title abbreviation: BMC Cancer
publication date: 2014-08-08T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 755385
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.

Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
PubMed Identifier: 25028469
author list: Zhang YX, Sicinska E, Czaplinski JT, Remillard SP, Moss S, Wang Y, Brain C, Loo A, Snyder EL, Demetri GD, Kim S, Kung AL, Wagner AJ
published in: Molecular cancer therapeutics
information resource reference: Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014 Sep; 13(9):2184-93.
journal title abbreviation: Mol Cancer Ther
publication date: 2014-07-15T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 545632
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.

Authorship 756201
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.
PubMed Identifier: 24852265
author list: Sioletic S, Czaplinski J, Hu L, Fletcher JA, Fletcher CD, Wagner AJ, Loda M, Demetri GD, Sicinska ET, Snyder EL
published in: The Journal of pathology
information resource reference: c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas. J Pathol. 2014 Oct; 234(2):190-202.
journal title abbreviation: J Pathol
publication date: 2014-08-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 362289
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

Authorship 762680
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.

Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.
PubMed Identifier: 24923260
author list: George S, Barysauskas C, Serrano C, Oduyebo T, Rauh-Hain JA, Del Carmen MG, Demetri GD, Muto MG
published in: Cancer
information resource reference: Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma. Cancer. 2014 Oct 15; 120(20):3154-8.
journal title abbreviation: Cancer
publication date: 2014-06-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 425442
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authorship 6885
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.

Authorship 484490
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Targeted approaches for the treatment of thrombocytopenia.

Authorship 769215
type: Authorship
author rank in publication: 13
linked author: Demetri, George
linked information resource: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.

Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
PubMed Identifier: 25374341
author list: Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GD
published in: BMC cancer
information resource reference: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813.
journal title abbreviation: BMC Cancer
publication date: 2014-11-05T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 452078
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.

Authorship 474729
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: The biology of GM-CSF: regulation of production and interaction with its receptor.

Authorship 515659
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

Authorship 569027
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.

Authorship 561081
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/958071

Authorship 564011
type: Authorship
author rank in publication: 16
linked author: Demetri, George
linked information resource: Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.

Authorship 276102
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins.

Authorship 289963
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.

Authorship 318925
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

Authorship 325624
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.

Authorship 528047
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Disease state awareness in sarcoma.

Authorship 59899
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.

Authorship 65286
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Cellular interaction regulating the production of colony-stimulating factors.

Authorship 71251
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.

Authorship 83663
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Regulation of granulocyte- and monocyte-colony stimulating factor mRNA levels in human blood monocytes is mediated primarily at a post-transcriptional level.

Authorship 387024
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies.

Authorship 417679
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).

Authorship 394185
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

Authorship 444926
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

Authorship 427271
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.

Authorship 434867
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib.

Authorship 448933
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

Authorship 353892
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.

Authorship 205410
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation.

Authorship 378272
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail?

Authorship 478705
type: Authorship
author rank in publication: 22
linked author: Demetri, George
linked information resource: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.

Authorship 529481
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authorship 544281
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma.

Authorship 554929
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.

Authorship 190794
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN Task Force report: gastrointestinal stromal tumor (GIST).

Authorship 320215
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.

Authorship 515917
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Update on new diagnostic and therapeutic approaches for sarcomas.

Authorship 56720
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.

Authorship 69265
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Clinical benefits of epoetin alfa therapy in patients with lung cancer.

Authorship 70215
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: The use of hematopoietic growth factors to support cytotoxic chemotherapy for patients with breast cancer.

Authorship 235503
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs).

Authorship 271202
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authorship 312976
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authorship 340108
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic.

Authorship 344494
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.

Authorship 210355
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Multimodality treatment of mesenteric desmoid tumours.

Authorship 367708
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.

Authorship 267040
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.

Authorship 328867
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.

Authorship 330152
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

Authorship 123143
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1177148

Authorship 21785
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Cancer- and treatment-related anemia.

Authorship 196478
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

Authorship 339710
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.

Authorship 371824
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Granulocyte-macrophage colony-stimulating factor (GM-CSF): preclinical and clinical investigations.

Authorship 389749
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Current management of metastatic gastrointestinal stromal tumor: a case report.

Authorship 459219
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Soft tissue sarcomas of adults: state of the translational science.

Authorship 474547
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Chemotherapy and neutropenia.

Authorship 4773
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.

Authorship 485715
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.

Authorship 44797
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Imaging features of bone metastases in patients with gastrointestinal stromal tumors.

Authorship 23380
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Gastrointestinal stromal tumors (GISTs).

Authorship 7974
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authorship 395135
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.

Authorship 266746
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.

Authorship 268481
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature.

Authorship 398011
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk.

Authorship 260531
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1027419

Authorship 45827
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.

Authorship 470739
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN: Sarcoma.

Authorship 477784
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.

Authorship 362193
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.

Authorship 377052
type: Authorship
author rank in publication: 20
linked author: Demetri, George
linked information resource: First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.

Authorship 554424
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.

Authorship 793780
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.

Authorship 804691
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.

Authorship 798393
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/56075253

Authorship 798409
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.

Authorship 798154
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.

Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial.
PubMed Identifier: 25882987
author list: Blay JY, Shen L, Kang YK, Rutkowski P, Qin S, Nosov D, Wan D, Trent J, Srimuninnimit V, Pápai Z, Le Cesne A, Novick S, Taningco L, Mo S, Green S, Reichardt P, Demetri GD
published in: The Lancet. Oncology
information resource reference: Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol. 2015 May; 16(5):550-60.
journal title abbreviation: Lancet Oncol
publication date: 2015-04-14T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
PubMed Identifier: 25641662
author list: Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD
published in: Cancer
information resource reference: Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer. 2015 05 01; 121(9):1405-13.
journal title abbreviation: Cancer
publication date: 2015-01-13T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/56075253
PubMed Identifier: 25864104
author list: Blay JY, Pápai Z, Tolcher AW, Italiano A, Cupissol D, López-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saâda-Bouzid E, Santoro A, Franke FA, Cohen P, Le-Guennec S, Demetri GD
published in: The Lancet. Oncology
information resource reference: Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015 May; 16(5):531-40.
journal title abbreviation: Lancet Oncol
publication date: 2015-04-08T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.

Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
PubMed Identifier: 25536954
author list: Choy E, Flamand Y, Balasubramanian S, Butrynski JE, Harmon DC, George S, Cote GM, Wagner AJ, Morgan JA, Sirisawad M, Mani C, Hornicek FJ, Duan Z, Demetri GD
published in: Cancer
information resource reference: Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30.
journal title abbreviation: Cancer
publication date: 2014-12-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.
PubMed Identifier: 25885530
author list: Wagner MJ, Amodu LI, Duh MS, Korves C, Solleza F, Manson SC, Diaz J, Neary MP, Demetri GD
published in: BMC cancer
information resource reference: A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments. BMC Cancer. 2015 Mar 25; 15:175.
journal title abbreviation: BMC Cancer
publication date: 2015-03-25T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 276921
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor.

Authorship 289406
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy.

Authorship 301910
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.

Authorship 334729
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma.

Authorship 480480
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Management of malignant gastrointestinal stromal tumours.

Authorship 517814
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.

Authorship 548120
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Hemopoietins and leukemia.

Authorship 542343
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Ecdysteroid-inducible polypeptides in a Drosophila cell line.

Authorship 813008
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.

Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion.
PubMed Identifier: 26070915
author list: Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martín-Broto J, Nishida T, Reichardt P, Schöffski P, Trent JC
published in: The oncologist
information resource reference: Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. Oncologist. 2015 Jul; 20(7):823-30.
journal title abbreviation: Oncologist
publication date: 2015-06-12T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 816153
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.

Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines.
PubMed Identifier: 25805798
author list: Goldberg JM, Fisher DE, Demetri GD, Neuberg D, Allsop SA, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm M, Canning C, Hodi FS, Dranoff G
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
journal title abbreviation: Clin Cancer Res
publication date: 2015-03-24T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 317485
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Authorship 327697
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study.

Authorship 816549
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment.

Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment.
PubMed Identifier: 26199562
author list: Tanguturi SK, George S, Marcus KJ, Demetri GD, Baldini EH
published in: Sarcoma
information resource reference: Whole Lung Irradiation in Adults with Metastatic Ewing Sarcoma: Practice Patterns and Implications for Treatment. Sarcoma. 2015; 2015:591698.
journal title abbreviation: Sarcoma
publication date: 2015-06-25T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 35081
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec.

Authorship 822055
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

Authorship 443743
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide.

Authorship 532832
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-colony-stimulating factor: implications for yield of hematopoietic progenitor cell collections.

Authorship 534459
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Authorship 88160
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Modifying phase I methodology to facilitate enrolment of molecularly selected patients.

Authorship 838081
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.

Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial.
PubMed Identifier: 25655899
author list: Komatsu Y, Doi T, Sawaki A, Kanda T, Yamada Y, Kuss I, Demetri GD, Nishida T
published in: International journal of clinical oncology
information resource reference: Regorafenib for advanced gastrointestinal stromal tumors following imatinib and sunitinib treatment: a subgroup analysis evaluating Japanese patients in the phase III GRID trial. Int J Clin Oncol. 2015 Oct; 20(5):905-12.
journal title abbreviation: Int J Clin Oncol
publication date: 2015-02-06T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 442576
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Clinical presentation and management of mTOR inhibitor-associated stomatitis.

Authorship 49875
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.

Authorship 50223
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Major response to imatinib mesylate in KIT-mutated melanoma.

Authorship 533331
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Markers of angiogenesis and clinical features in patients with sarcoma.

Authorship 851180
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.
PubMed Identifier: 26644247
author list: Bellinger AM, Arteaga CL, Force T, Humphreys BD, Demetri GD, Druker BJ, Moslehi JJ
published in: Circulation
information resource reference: Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation. 2015 Dec 08; 132(23):2248-58.
journal title abbreviation: Circulation
publication date: 2015-12-08T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 538779
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in vivo.

Authorship 856480
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/62708872

https://connects.catalyst.harvard.edu/Profiles/profile/62708872
PubMed Identifier: 26699729
author list: Yoo C, Ryu MH, Nam BH, Ryoo BY, Demetri GD, Kang YK
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT). Eur J Cancer. 2016 Jan; 52:201-8.
journal title abbreviation: Eur J Cancer
publication date: 2015-12-14T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Impact of imatinib rechallenge on health-related quality of life in patients with TKI-refractory gastrointestinal stromal tumours: Sub-analysis of the placebo-controlled, randomised phase III trial (RIGHT).

Authorship 499614
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Tissue factor gene expression in acute myeloblastic leukemia.

Authorship 50293
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Stem cell factor is a potent synergistic factor in hematopoiesis.

Authorship 558269
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

Authorship 857843
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.

Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial.
PubMed Identifier: 26772734
author list: Reichardt P, Demetri GD, Gelderblom H, Rutkowski P, Im SA, Gupta S, Kang YK, Schöffski P, Schuette J, Soulières D, Blay JY, Goldstein D, Fly K, Huang X, Corsaro M, Lechuga MJ, Martini JF, Heinrich MC
published in: BMC cancer
information resource reference: Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer. 2016 Jan 15; 16:22.
journal title abbreviation: BMC Cancer
publication date: 2016-01-15T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 74096
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: A phase I trial of recombinant human tumor necrosis factor and interferon-gamma: effects of combination cytokine administration in vivo.

Authorship 88782
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.

Authorship 862025
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.

Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
PubMed Identifier: 26371143
author list: Demetri GD, von Mehren M, Jones RL, Hensley ML, Schuetze SM, Staddon A, Milhem M, Elias A, Ganjoo K, Tawbi H, Van Tine BA, Spira A, Dean A, Khokhar NZ, Park YC, Knoblauch RE, Parekh TV, Maki RG, Patel SR
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
journal title abbreviation: J Clin Oncol
publication date: 2015-09-14T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 99383
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.

Authorship 295820
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: High-dose ifosfamide in the treatment of sarcomas of soft tissues and bone.

Authorship 317162
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.

Authorship 326105
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Authorship 875026
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.

A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
PubMed Identifier: 26865352
author list: Ben Ami E, Demetri GD
published in: Expert opinion on drug safety
information resource reference: A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opin Drug Saf. 2016; 15(4):571-8.
journal title abbreviation: Expert Opin Drug Saf
publication date: 2016-02-27T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 402642
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography.

Authorship 878540
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.
PubMed Identifier: 26874885
author list: Schöffski P, Chawla S, Maki RG, Italiano A, Gelderblom H, Choy E, Grignani G, Camargo V, Bauer S, Rha SY, Blay JY, Hohenberger P, D'Adamo D, Guo M, Chmielowski B, Le Cesne A, Demetri GD, Patel SR
published in: Lancet (London, England)
information resource reference: Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16; 387(10028):1629-37.
journal title abbreviation: Lancet
publication date: 2016-02-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 424992
type: Authorship
author rank in publication: 22
linked author: Demetri, George
linked information resource: KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Authorship 44314
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Soft tissue sarcoma.

Authorship 456807
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Advances in the treatment of gastrointestinal stromal tumours.

Authorship 460077
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.

Authorship 883317
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.

Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.
PubMed Identifier: 26918731
author list: Nakayama R, Zhang YX, Czaplinski JT, Anatone AJ, Sicinska ET, Fletcher JA, Demetri GD, Wagner AJ
published in: Oncotarget
information resource reference: Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget. 2016 Mar 29; 7(13):16581-92.
journal title abbreviation: Oncotarget
publication date: 2016-03-29T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 536023
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Hematopoietic growth factors: current knowledge, future prospects.

Authorship 884402
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.

Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour.
PubMed Identifier: 27156227
author list: Wagner AJ, Agulnik M, Heinrich MC, Mahadevan D, Riedel RF, von Mehren M, Trent J, Demetri GD, Corless CL, Yule M, Lyons JF, Oganesian A, Keer H
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour. Eur J Cancer. 2016 07; 61:94-101.
journal title abbreviation: Eur J Cancer
publication date: 2016-05-05T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 550109
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Impact of hematopoietic growth factors on the management of small-cell lung cancer.

Authorship 99367
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival.

Authorship 554205
type: Authorship
author rank in publication: 37
linked author: Demetri, George
linked information resource: A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Assistant Professor
sort order: 2
type: Faculty Rank

Associate Professor
sort order: 1
type: Faculty Rank

Full Professor
sort order: 0
type: Faculty Rank

Other Faculty
sort order: 5
type: Faculty Rank

Authorship 66214
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

450 Brookline Ave
type: Address
address line 1: Dana-Farber Cancer Institute
address line 2: Ludwig Center and Sarcoma Center, Dana 2-107
address line 3: 450 Brookline Ave
city: Boston
postal code: 02215
state or province: MA

Authorship 575644
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Beyond supportive care: what are the next questions in the use of hematopoietic cytokines with cytotoxic chemotherapy?

Authorship 5956
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: GIST 1, chemotherapy 0, with a brand new hitter up next.

Authorship 506460
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.

Authorship 515872
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

Authorship 51969
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.

Authorship 911211
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/67956094

https://connects.catalyst.harvard.edu/Profiles/profile/67956094
PubMed Identifier: 27371698
author list: Ben-Ami E, Barysauskas CM, von Mehren M, Heinrich MC, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Yap JT, Van den Abbeele AD, Solomon SM, Fletcher JA, Demetri GD, George S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy. Ann Oncol. 2016 09; 27(9):1794-9.
journal title abbreviation: Ann Oncol
publication date: 2016-07-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer
end date: 2025-05-31
principal investigator name: SELLERS, WILLIAM R
start date: 2007-04-01
type: Grant
sponsor award id: P50CA127003

Co-Principal Investigator
type: Researcher Role
researcher role of: Demetri, George
contributes to: Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer

Authorship 477930
type: Authorship
author rank in publication: 19
linked author: Demetri, George
linked information resource: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

Authorship 533366
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Clinical management of gastrointestinal stromal tumors: before and after STI-571.

Authorship 548659
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Angiosarcoma.

Authorship 57899
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma.

Authorship 65703
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Diagnosis in oncology. Askin tumor.

Authorship 209895
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: mTOR inhibitors in sarcoma.

Authorship 234074
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.

Authorship 265654
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

Authorship 34756
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence.

Authorship 36540
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Authorship 942143
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Advances and controversies in the management of soft tissue sarcomas.

Authorship 941802
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.

Authorship 941414
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors.

Authorship 942164
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST).

Authorship 941910
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer.

Authorship 944204
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71515108

Authorship 941801
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST.

Authorship 942048
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.

Authorship 941097
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST).

Authorship 940659
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Evaluation of SRC-family kinases in gastrointestinal stromal tumors.

Authorship 940989
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors.

Authorship 940778
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL).

Authorship 941550
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).

Authorship 942890
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.

Authorship 942891
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance.

Authorship 942160
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.

Authorship 943734
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium.

Authorship 943914
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Tales of Personalized Cancer Treatment.

Authorship 942279
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU).

Authorship 941837
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Real world treatment patterns of gastrointestinal stromal tumor patients.

Authorship 942161
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas.

Authorship 943883
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.

Authorship 944027
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors.

Authorship 942039
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Sunitinib treatment of pediatric metastatic GIST after failure of imatinib.

Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance.
PubMed Identifier: 27952838
author list: Casali PG, Garrett CR, Blackstein ME, Shah M, Verweij J, McArthur G, Judson I, Li J, Baum CM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9513.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status.
PubMed Identifier: 27952818
author list: Heinrich MC, Maki RG, Corless CL, Antonescu CR, Fletcher JA, Fletcher CD, Huang X, Baum CM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9502.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Tales of Personalized Cancer Treatment.
PubMed Identifier: 27987546
author list: Demetri G
published in: Seminars in nephrology
information resource reference: Tales of Personalized Cancer Treatment. Semin Nephrol. 2016 11; 36(6):462-467.
journal title abbreviation: Semin Nephrol
publication date: 2016-11-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST.
PubMed Identifier: 27952786
author list: George S, Casali PG, Blay J, Le Cesne A, Tyler AR, Quigley MT, Tassell V, Baum CM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II study of sunitinib administered in a continuous daily dosing regimen in patients (pts) with advanced GIST. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9532.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST).
PubMed Identifier: 27955213
author list: Van Den Abbeele AD, Barnes AS, De Vries DJ, Yap JT, Reichardt P, Casalli PG, Von Mehren M, O'Neel J, Hayes W, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Assessment of response using FDG-PET and CT in a phase I study of AMN107 alone or in combination with imatinib (IM) in patients with imatinib-resistant (IM-R) gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):3087.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71515108
PubMed Identifier: 27963700
author list: Demetri GD, Schuetze S, Blay J, Chawla S, von Mehren M, Casali P, Morris D, Bayever E, Alfaro V, LeCesne A
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide. J Clin Oncol. 2009 May 20; 27(15_suppl):10509.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide.

A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL).
PubMed Identifier: 27963914
author list: Gronchi A, Le Cesne A, Bui NB, Palmerini E, Demetri G, Hohenberger P, Hohl RJ, Pilotti S, Perez I, Lardelli P
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL). J Clin Oncol. 2009 May 20; 27(15_suppl):10525.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas.
PubMed Identifier: 27952813
author list: Chawla SP, Tolcher AW, Staddon AP, Schuetze SM, D'Amato GZ, Blay JY, Sankhala KK, Daly ST, Rivera VM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9505.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium.
PubMed Identifier: 27987543
author list: Greka A, Gibson D, Mundel P, Demetri G, Hildebrandt F, Pollak M, Florez J
published in: Seminars in nephrology
information resource reference: Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium. Semin Nephrol. 2016 11; 36(6):448.
journal title abbreviation: Semin Nephrol
publication date: 2016-11-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST).
PubMed Identifier: 27952946
author list: Raut CP, Van Den Abbeele A, Ramaiya N, Morgan JA, George S, Quigley MT, Dollard AM, Bertagnolli MM, Baum C, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Patterns of PET response after long-term sunitinib therapy in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9547.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
PubMed Identifier: 27952948
author list: Reichardt P, Casali PG, Blay J, Von Mehren M, Schoffski P, Hosseinzadeh S, Tanaka C, Gsponer T, Veronese ML, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2006 Jun 20; 24(18_suppl):9545.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Sunitinib treatment of pediatric metastatic GIST after failure of imatinib.
PubMed Identifier: 27952833
author list: Janeway KA, Matthews DC, Butrynski JE, D'Amato GZ, Agresta S, Garrett C, Corless CL, Albritton KH, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Sunitinib treatment of pediatric metastatic GIST after failure of imatinib. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9519.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate.
PubMed Identifier: 27952792
author list: Blanke CD, Demetri GD, Von Mehren M, Heinrich MC, Eisenberg BL, Fletcher J, Corless CL, Wehrle E, Sandau KB, Joensuu H
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9528.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial.
PubMed Identifier: 27952801
author list: Morgan JA, Garrett CR, Schutte HJ, Hurwitz H, Rosen LS, Ruka W, Picus J, Kaiser P, Baum CM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: Early results from a "treatment-use" trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9540.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU).
PubMed Identifier: 27985734
author list: George S, Lechner T, Li S, Cohen DP, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Hypertension (HTN) as a potential biomarker of efficacy in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU). J Clin Oncol. 2011 Feb; 29(4_suppl):38.
journal title abbreviation: J Clin Oncol
publication date: 2011-02-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Evaluation of SRC-family kinases in gastrointestinal stromal tumors.
PubMed Identifier: 27952790
author list: Bauer S, Demetri GD, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Evaluation of SRC-family kinases in gastrointestinal stromal tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9529.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Real world treatment patterns of gastrointestinal stromal tumor patients.
PubMed Identifier: 27962678
author list: Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsaneva M, Yu AP, Wu E, Signorovitch J, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Real world treatment patterns of gastrointestinal stromal tumor patients. J Clin Oncol. 2009 May 20; 27(15_suppl):e15602.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer.
PubMed Identifier: 27963557
author list: MacRae C, Richardson PG, Walker J, Grayzel DS, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):e14539.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Advances and controversies in the management of soft tissue sarcomas.
PubMed Identifier: 27918199
author list: Demetri GD, Blay JY, Casali PG
published in: Future oncology (London, England)
information resource reference: Advances and controversies in the management of soft tissue sarcomas. Future Oncol. 2017 Jan; 13(1s):3-11.
journal title abbreviation: Future Oncol
publication date: 2017-01-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas.
PubMed Identifier: 27952809
author list: Grosso F, Demetri GD, Blay JY, Judson I, Le Cesne A, Spreafico C, Jimeno J, Pilotti S, D'Incalci M, Casali PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9511.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors.
PubMed Identifier: 27961298
author list: Cioffi A, LeCesne A, Blay J, Delaloge S, Yovine A, Maki R, Nieto A, Jiao JJ, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Trabectedin phase II clinical trials: Pooled analysis of safety in patients with solid tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):e13510.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors.
PubMed Identifier: 27961683
author list: George S, Lal R, Camidge DR, Arkenau H, Chick J, Poondru S, Yap TA, Eckhardt SG, Demetri GD, Scurr M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):3564.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors.
PubMed Identifier: 27963690
author list: Goldberg J, Demetri GD, Choy E, Rosen L, Pappo A, Dubois S, Geller J, Chai F, Ferrari D, Wagner AJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Preliminary results from a phase II study of ARQ 197 in patients with microphthalmia transcription factor family (MiT)-associated tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):10502.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.
PubMed Identifier: 27961289
author list: Wagner AJ, Von Hoff DH, LoRusso PM, Tibes R, Mazina KE, Ware JA, Yan Y, Derynck MK, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol. 2009 May 20; 27(15_suppl):3501.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-20T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 944594
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

Authorship 944679
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.

Authorship 944575
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).

Authorship 945569
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions.

Authorship 944828
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.

Authorship 945563
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71645802

Authorship 944974
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx).

Authorship 944596
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: High rates of histopathologic discordance in sarcoma with implications for clinical care.

Authorship 944635
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).

Authorship 945103
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Induction of TRAIL and XAF-1 and inhibition of p-Akt and c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cells.

Authorship 945447
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.

Authorship 944700
type: Authorship
author rank in publication: 16
linked author: Demetri, George
linked information resource: A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).

Authorship 945446
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS).

Authorship 945357
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

Authorship 945026
type: Authorship
author rank in publication: 19
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71646206

Authorship 945467
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.

Authorship 944793
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71646702

Authorship 946009
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/71646586

https://connects.catalyst.harvard.edu/Profiles/profile/71645802
PubMed Identifier: 28013625
author list: Samuels BL, Rushing D, Chawla SP, Schuetze SM, Von Mehren M, Keohan ML, O'Donovan M, Wei X, Sternas LA, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9000.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy.

Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033.
PubMed Identifier: 28013696
author list: Rankin C, Von Mehren M, Blanke C, Benjamin R, Fletcher CD, Bramwell V, Crowley J, Borden E, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9005.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Induction of TRAIL and XAF-1 and inhibition of p-Akt and c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cells.
PubMed Identifier: 28013748
author list: Borden EC, Jacobs B, Demetri G, Fletcher J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Induction of TRAIL and XAF-1 and inhibition of p-Akt and c-Kit expression by interferons (IFNs) is associated with apoptosis in GIST cells. J Clin Oncol. 2004 Jul 15; 22(14_suppl):9027.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST).
PubMed Identifier: 28015171
author list: Holdsworth CH, Manola J, Badawi RD, Israel DA, Blanke C, Von Mehren M, Joensuu HT, Dimitrijevic S, Demetri GD, Van Den Abbeele AD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Use of computerized tomography (CT) as an early prognostic indicator of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3011.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning.
PubMed Identifier: 28015172
author list: Van Den Abbeele AD, Badawi RD, Manola J, Morgan JA, Desai J, Kazanovicz A, Armand MS, Baum C, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3012.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71646206
PubMed Identifier: 28021073
author list: Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui Nguyen B, Cranmer LD, Reichardt P, Bompas E, Song Y, Lee R, Eid JE, Loewy J, Haluska FG, Dodion PF, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol. 2011 May 20; 29(15_suppl):10005.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).

A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors.
PubMed Identifier: 28022582
author list: Von Hoff DD, LoRusso P, Demetri GD, Weiss GJ, Shapiro G, Ramanathan RK, Ware JA, Raja R, Jin J, Levy GG, Mazina KE, Wagner AJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I dose-escalation study to evaluate GDC-0941, a pan-PI3K inhibitor, administered QD or BID in patients with advanced or metastatic solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):3052.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS).
PubMed Identifier: 28013692
author list: Morgan JA, George S, Desai J, St Amand M, Horton D, Wilkins E, Manola J, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II study of gemcitabine/vinorelbine (GV) as first or second line chemotherapy in patients with metastatic soft tissue sarcoma (STS). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9009.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132.
PubMed Identifier: 28021247
author list: Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno SH, Kane JM, vonMehren M, Eisenberg BL
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Long-term follow-up results of RTOG 0132. J Clin Oncol. 2011 May 20; 29(15_suppl):10057.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU).
PubMed Identifier: 28021071
author list: George S, von Mehren M, Heinrich MC, Wang Q, Corless CL, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Manola J, Yap JT, Van Den Abbeele AD, Solomon S, Fletcher JA, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A multicenter phase II study of regorafenib in patients (pts) with advanced gastrointestinal stromal tumor (GIST), after therapy with imatinib (IM) and sunitinib (SU). J Clin Oncol. 2011 May 20; 29(15_suppl):10007.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).
PubMed Identifier: 28021121
author list: von Mehren M, Heinrich MC, Joensuu H, Blanke CD, Wehrle E, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol. 2011 May 20; 29(15_suppl):10016.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

High rates of histopathologic discordance in sarcoma with implications for clinical care.
PubMed Identifier: 28021289
author list: Raut CP, George S, Hornick JL, Butrynski JE, Morgan JA, Ready J, Nascimento AF, Fletcher CD, Demetri GD, Baldini EH
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: High rates of histopathologic discordance in sarcoma with implications for clinical care. J Clin Oncol. 2011 May 20; 29(15_suppl):10065.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71646586
PubMed Identifier: 28015179
author list: Van Oosterom AT, Dumez H, Desai J, Stroobants S, Van Den Abbeele AD, Clement P, Shand N, Kovarik J, Tsyrlova A, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3002.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM.

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
PubMed Identifier: 28021119
author list: Demetri GD, Heinrich MC, Chmielowski B, Morgan JA, George S, Bradley R, Blackman RK, Teofilovici F, Fletcher JA, Tap WD, von Mehren M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST. J Clin Oncol. 2011 May 20; 29(15_suppl):10011.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST).
PubMed Identifier: 28015182
author list: Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CD, Kazanovicz A, Van Den Abbeele A, Baum C, Maki R, Heinrich MC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2004 Jul 15; 22(14_suppl):3001.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx).
PubMed Identifier: 28021167
author list: Van Den Abbeele AD, Tanaka Y, Locascio T, Sakellis C, Heinrich MC, von Mehren M, Choy E, Tap WD, Manola J, Demetri GD, George S, Yap JT
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Assessment of regorafenib activity with FDG-PET/CT in a multicenter phase II study in patients (pts) with advanced gastrointestinal stromal tumor (GIST) following failure of standard therapy (Rx). J Clin Oncol. 2011 May 20; 29(15_suppl):10050.
journal title abbreviation: J Clin Oncol
publication date: 2011-05-20T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/71646702
PubMed Identifier: 28013747
author list: Dileo P, Randhawa R, Vansonnenberg E, Shankar S, Desai J, Morgan JA, Tuncali K, Van Den Abbeele A, Silverman SG, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9024.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM).

Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions.
PubMed Identifier: 28015168
author list: Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Tuncali K, Silverman SG, Van Den Abbeele AD, Vansonnenberg E, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clonal evolution of resistance to imatinib (IM) in patients (pts) with gastrointestinal stromal tumor (GIST): molecular and radiologic evaluation of new lesions. J Clin Oncol. 2004 Jul 15; 22(14_suppl):3010.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 447239
type: Authorship
author rank in publication: 48
linked author: Demetri, George
linked information resource: High-throughput oncogene mutation profiling in human cancer.

Authorship 955442
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/72395710

Authorship 955546
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).

Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).
PubMed Identifier: 28147724
author list: Maki RG, Italiano A, Gelderblom H, Grignani G, Camargo VP, Bauer S, Rha SY, Chawla SP, Blay JY, Hohenberger P, D'Adamo DR, Wang B, Chmielowski B, Le Cesne A, Demetri GD, Patel S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI). J Clin Oncol. 2015 Jun 20; 33(18_suppl):LBA10502.
journal title abbreviation: J Clin Oncol
publication date: 2015-06-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/72395710
PubMed Identifier: 28136079
author list: Ryu MH, Ryoo BY, Kim HJ, Lee JJ, Yoo C, Nam BH, Ramaiya N, Jagannathan JP, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study. J Clin Oncol. 2013 Jun 20; 31(18_suppl):LBA10502.
journal title abbreviation: J Clin Oncol
publication date: 2013-06-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study.

Authorship 63037
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression.

Authorship 64293
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Challenges in the development of platelet growth factors: low expectations for low counts.

Authorship 957534
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.

Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033.
PubMed Identifier: 28196207
author list: Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, von Mehren M, Blackstein ME, Priebat DA, Tap WD, Maki RG, Corless CL, Fletcher JA, Owzar K, Crowley JJ, Benjamin RS, Baker LH
published in: JAMA oncology
information resource reference: Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017 Jul 01; 3(7):944-952.
journal title abbreviation: JAMA Oncol
publication date: 2017-07-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 7333
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.

Authorship 87499
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1126017

Authorship 93511
type: Authorship
author rank in publication: 11
linked author: Demetri, George
linked information resource: A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.

Authorship 957936
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
PubMed Identifier: 28228279
author list: George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM
published in: Immunity
information resource reference: Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017 02 21; 46(2):197-204.
journal title abbreviation: Immunity
publication date: 2017-02-21T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
PubMed Identifier: 9053493
author list: Shapiro CL, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997 Feb; 15(2):674-83.
journal title abbreviation: J Clin Oncol
publication date: 1997-02-01T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Soft tissue sarcomas of adults: state of the translational science.
PubMed Identifier: 12796356
author list: Borden EC, Baker LH, Bell RS, Bramwell V, Demetri GD, Eisenberg BL, Fletcher CD, Fletcher JA, Ladanyi M, Meltzer P, O'Sullivan B, Parkinson DR, Pisters PW, Saxman S, Singer S, Sundaram M, van Oosterom AT, Verweij J, Waalen J, Weiss SW, Brennan MF
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res. 2003 Jun; 9(6):1941-56.
journal title abbreviation: Clin Cancer Res
publication date: 2003-06-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease.
PubMed Identifier: 12957451
author list: Demetri GD
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: OncoloGIST, BioloGIST, RadioloGIST: the big impact on the field of oncology of a molecularly-targeted therapy designed to treat a rare disease. Eur J Cancer. 2003 Sep; 39(14):1976-7.
journal title abbreviation: Eur J Cancer
publication date: 2003-09-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
PubMed Identifier: 16682719
author list: Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006 Jul 01; 24(19):3187-205.
journal title abbreviation: J Clin Oncol
publication date: 2006-05-08T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes.
PubMed Identifier: 15735689
author list: Oliveira AM, Perez-Atayde AR, Dal Cin P, Gebhardt MC, Chen CJ, Neff JR, Demetri GD, Rosenberg AE, Bridge JA, Fletcher JA
published in: Oncogene
information resource reference: Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. Oncogene. 2005 May 12; 24(21):3419-26.
journal title abbreviation: Oncogene
publication date: 2005-05-12T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 960957
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial.

Authorship 960932
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505.

Authorship 965110
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000.

Authorship 960471
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Reply to S. Rastogi et al.

Authorship 960328
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET.

Authorship 965392
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure.

Authorship 965117
type: Authorship
author rank in publication: 7
linked author: Demetri, George
linked information resource: Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S.

Authorship 965358
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial.

Authorship 960952
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST.

Authorship 965158
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST.

Authorship 960930
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/76071073

Authorship 965145
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST).

Authorship 965357
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis.

Authorship 965119
type: Authorship
author rank in publication: 8
linked author: Demetri, George
linked information resource: A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update.

Authorship 965897
type: Authorship
author rank in publication: 4
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/76070903

Authorship 966326
type: Authorship
author rank in publication: 5
linked author: Demetri, George
linked information resource: Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+).

Authorship 965923
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST).

Authorship 960929
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).

Authorship 964434
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST).

Authorship 965350
type: Authorship
author rank in publication: 2
linked author: Demetri, George
linked information resource: A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS).

Authorship 965955
type: Authorship
author rank in publication: 6
linked author: Demetri, George
linked information resource: KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies.

Authorship 966238
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors.

Authorship 960924
type: Authorship
author rank in publication: 9
linked author: Demetri, George
linked information resource: Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST.

Authorship 965880
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan.

Authorship 965467
type: Authorship
author rank in publication: 10
linked author: Demetri, George
linked information resource: A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update.

Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis.
PubMed Identifier: 27948505
author list: George S, Blay JY, Casali PG, Le Cesne A, DePrimo SE, Harmon CS, Law CN, Tassell V, Baum CM, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. J Clin Oncol. 2008 May 20; 26(15_suppl):10554.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update.
PubMed Identifier: 27945575
author list: van Oosterom A, Reichardt P, Blay JY, Dumez H, Fletcher J, Debiec-Rychter M, Shand N, Drimitrijevic S, Yap A, Demetri G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update. J Clin Oncol. 2005 Jun; 23(16_suppl):9033.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET.
PubMed Identifier: 27948364
author list: Van den Abbeele AD, Yap JT, Rastarhuyeva I, Akhurst T, Keohan ML, George S, Bhuchar G, Morgan JA, Demetri GD, Maki RG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Early metabolic response to continuous daily dosing of sunitinib in soft tissue sarcomas (STS) other than GIST using FDG- PET. J Clin Oncol. 2008 May 20; 26(15_suppl):10529.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/76070903
PubMed Identifier: 27949658
author list: Lal R, Camidge DR, George S, Demetri GD, Eckhardt SG, Stephens A, Chick J, Boinpally R, Kaye SB, Scurr M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors. J Clin Oncol. 2008 May 20; 26(15_suppl):3553.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource
label: A phase I, dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930, an oral tyrosine kinase inhibitor (TKI), in patients (pts) with advanced solid tumors.

A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS).
PubMed Identifier: 27945531
author list: Baker LH, Demetri GD, Mendelson DS, Rowinsky EK, McKeegan EM, Knight RA, Carlson DM, Lobell M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS). J Clin Oncol. 2005 Jun; 23(16_suppl):9013.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST.
PubMed Identifier: 27944340
author list: Demetri GD, van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, McArthur G, Judson I, Baum CM, Casali PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. J Clin Oncol. 2005 Jun; 23(16_suppl):4000.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S.
PubMed Identifier: 27948304
author list: Butrynski JE, Duh MS, Fournier A, Moyneur E, Dial E, Neary MP, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Soft tissue sarcoma (STS): Challenges in identification, treatment patterns, and costs of disease management in the U.S. J Clin Oncol. 2008 May 20; 26(15_suppl):10573.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/76071073
PubMed Identifier: 27948417
author list: Wagner AJ, Morgan JA, Chugh R, Rosen LS, George S, Gordon MS, Devine CM, Van den Abbeele AD, Grayzel D, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10503.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial.

Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST).
PubMed Identifier: 27945533
author list: Maki RG, Fletcher JA, Heinrich MC, Morgan JA, George S, Desai J, Scheu K, Fletcher CD, Baum C, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9011.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST).
PubMed Identifier: 27949093
author list: von Mehren M, Wang Y, Joensuu H, Blanke CD, Wehrle E, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Imatinib pharmacokinetics (PK) and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2008 May 20; 26(15_suppl):4523.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update.
PubMed Identifier: 27948504
author list: Blay JY, Casali PG, Reichardt P, von Mehren M, Debiec-Rychter M, Bailey S, Veronese ML, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update. J Clin Oncol. 2008 May 20; 26(15_suppl):10553.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure.
PubMed Identifier: 27948367
author list: Demetri GD, Huang X, Garrett CR, Schöffski P, Blackstein ME, Shah MH, Verweij J, Tassell V, Baum CM, Casali PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs. placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol. 2008 May 20; 26(15_suppl):10524.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST.
PubMed Identifier: 27945574
author list: Norden-Zfoni A, Manola J, Desai J, Morgan J, Bello CL, Deprimo SE, Shalinsky DR, Baum C, Demetri GD, Heymach J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST. J Clin Oncol. 2005 Jun; 23(16_suppl):9036.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors.
PubMed Identifier: 27945784
author list: Evans TR, Morgan JA, van den Abbeele AD, McPherson IR, George S, Crawford D, Mastrullo JM, Cheng S, Fletcher JA, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):3034.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505.
PubMed Identifier: 27948564
author list: Ryan CW, von Mehren M, Rankin CJ, Goldblum JR, Demetri GD, Bramwell VH, Borden EC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. J Clin Oncol. 2008 May 20; 26(15_suppl):10532.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST.
PubMed Identifier: 27948507
author list: Reichardt P, Kang Y, Ruka W, Seddon B, Guerriero A, Breazna A, Lowry S, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Detailed analysis of survival and safety with sunitinib (SU) in a worldwide treatment-use trial of patients with advanced GIST. J Clin Oncol. 2008 May 20; 26(15_suppl):10548.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial.
PubMed Identifier: 27948539
author list: Keohan ML, Morgan JA, D'Adamo DR, Harmon D, Butrynski JE, Wagner AJ, Schwartz GK, Maki RG, Demetri GD, George S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial. J Clin Oncol. 2008 May 20; 26(15_suppl):10533.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST).
PubMed Identifier: 27948399
author list: Dumez H, Reichard P, Blay JY, Schöffski P, Morgan JA, Ray-Coquard IL, Hollaender N, Jappe A, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). J Clin Oncol. 2008 May 20; 26(15_suppl):10519.
journal title abbreviation: J Clin Oncol
publication date: 2008-05-20T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan.
PubMed Identifier: 27945569
author list: Sankhala KK, Chawla SP, Iagaru A, Dellamaggiora R, Chua V, Daly S, Bedrosian CL, Edwards GK, Cohen S, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Early response evaluation of therapy with AP23573 (an mTOR inhibitor) in sarcoma using [18F]2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scan. J Clin Oncol. 2005 Jun; 23(16_suppl):9028.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST).
PubMed Identifier: 27945527
author list: van den Abbeele A, Melenevsky Y, de Vries D, Manola J, Dileo P, Tetrault R, Baum C, Badawi R, Demetri G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Imaging kinase target inhibition with SU11248 by FDG-PET in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (I-R GIST). J Clin Oncol. 2005 Jun; 23(16_suppl):9006.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Reply to S. Rastogi et al.
PubMed Identifier: 27458282
author list: Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Reply to S. Rastogi et al. J Clin Oncol. 2016 10 10; 34(29):3583.
journal title abbreviation: J Clin Oncol
publication date: 2016-10-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial.
PubMed Identifier: 27945535
author list: Blackstein ME, Rankin C, Fletcher C, Heinrich M, Benjamin R, von Mehren M, Blanke C, Fletcher JA, Borden E, Demetri G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clinical benefit of imatinib in patients (pts) with metastatic gastrointestinal stromal tumors (GIST) negative for the expression of CD117 in the S0033 trial. J Clin Oncol. 2005 Jun; 23(16_suppl):9010.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+).
PubMed Identifier: 27946616
author list: Heinrich MC, Shoemaker JS, Corless CL, Hollis D, Demetri GD, Bertagnolli MM, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Correlation of target kinase genotype with clinical activity of imatinib mesylate (IM) in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+). J Clin Oncol. 2005 Jun; 23(16_suppl):7.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000.
PubMed Identifier: 27945526
author list: Dematteo RP, Antonescu CR, Chadaram V, You YN, McCall L, Maki R, Murgo A, Demetri G, Pisters P, Brennan MF
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: Safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol. 2005 Jun; 23(16_suppl):9009.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies.
PubMed Identifier: 27945576
author list: Bauer S, Hubert C, Heinrich MC, Cohen P, Bertagnolli M, Demetri GD, Fletcher J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: KIT hyperactivation in imatinib-resistant GIST: Implications for salvage therapies. J Clin Oncol. 2005 Jun; 23(16_suppl):9034.
journal title abbreviation: J Clin Oncol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Angiosarcoma.
PubMed Identifier: 9193372
author list: Vonderheide RH, Fleming MD, Carter G, Singer S, Demetri G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Angiosarcoma. J Clin Oncol. 1997 Apr; 15(4):1708-9.
journal title abbreviation: J Clin Oncol
publication date: 1997-04-01T00:00:00
year: 1997
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 968838
type: Authorship
author rank in publication: 18
linked author: Demetri, George
linked information resource: MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.
PubMed Identifier: 28270683
author list: Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA
published in: Nature communications
information resource reference: MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun. 2017 03 08; 8:14674.
journal title abbreviation: Nat Commun
publication date: 2017-03-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Cellular interaction regulating the production of colony-stimulating factors.
PubMed Identifier: 2189136
author list: Griffin JD, Demetri GD, Kanakura Y, Cannistra SA, Ernst TJ
published in: Progress in clinical and biological research
information resource reference: Cellular interaction regulating the production of colony-stimulating factors. Prog Clin Biol Res. 1990; 338:129-41.
journal title abbreviation: Prog Clin Biol Res
publication date: 1990-01-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer.
PubMed Identifier: 10984506
author list: Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM, Kantoff PW
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci U S A. 2000 Sep 26; 97(20):10990-5.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2000-09-26T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of soft-tissue sarcomas: an overview and update.
PubMed Identifier: 11905672
author list: Singer S, Demetri GD, Baldini EH, Fletcher CD
published in: The Lancet. Oncology
information resource reference: Management of soft-tissue sarcomas: an overview and update. Lancet Oncol. 2000 Oct; 1:75-85.
journal title abbreviation: Lancet Oncol
publication date: 2000-10-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors.
PubMed Identifier: 18521081
author list: Ou WB, Zhu MJ, Demetri GD, Fletcher CD, Fletcher JA
published in: Oncogene
information resource reference: Protein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumors. Oncogene. 2008 Sep 18; 27(42):5624-34.
journal title abbreviation: Oncogene
publication date: 2008-06-02T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 972282
type: Authorship
author rank in publication: 3
linked author: Demetri, George
linked information resource: Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.

Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting.
PubMed Identifier: 28334361
author list: Heinrich MC, Corless CL, Demetri GD
published in: JAMA oncology
information resource reference: Defining the Impact of Adjuvant Therapy in Molecularly Defined Subsets of Gastrointestinal Stromal Tumor : From Lumping to Splitting. JAMA Oncol. 2017 05 01; 3(5):597-599.
journal title abbreviation: JAMA Oncol
publication date: 2017-05-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
PubMed Identifier: 20457867
author list: Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010 Apr; 8 Suppl 2:S1-41; quiz S42-4.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2010-04-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network.
PubMed Identifier: 8953602
author list: Demetri G, Elias A, Gershenson D, Fossella F, Grecula J, Mittal B, Raschko J, Robertson J
published in: Oncology (Williston Park, N.Y.)
information resource reference: NCCN Small-Cell Lung Cancer Practice Guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Nov; 10(11 Suppl):179-94.
journal title abbreviation: Oncology (Williston Park)
publication date: 1996-11-01T00:00:00
year: 1996
type: Academic Article
type: Article
type: Document
type: Information Resource

Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma.
PubMed Identifier: 10526294
author list: Friedberg JW, Van den Abbeele AD, Kehoe K, Singer S, Fletcher CD, Demetri GD
published in: Cancer
information resource reference: Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. Cancer. 1999 Oct 15; 86(8):1621-7.
journal title abbreviation: Cancer
publication date: 1999-10-15T00:00:00
year: 1999
type: Academic Article
type: Article
type: Document
type: Information Resource

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
PubMed Identifier: 11287975
author list: Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker B, Demetri GD
published in: The New England journal of medicine
information resource reference: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001 Apr 05; 344(14):1052-6.
journal title abbreviation: N Engl J Med
publication date: 2001-04-05T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
PubMed Identifier: 12637460
author list: Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):976-83.
journal title abbreviation: J Clin Oncol
publication date: 2003-03-15T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma.
PubMed Identifier: 15520069
author list: Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004 Nov; 15(11):1667-72.
journal title abbreviation: Ann Oncol
publication date: 2004-11-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Gastrointestinal stromal tumors (GISTs).
PubMed Identifier: 15703627
author list: Saund MS, Demetri GD, Ashley SW
published in: Current opinion in gastroenterology
information resource reference: Gastrointestinal stromal tumors (GISTs). Curr Opin Gastroenterol. 2004 Mar; 20(2):89-94.
journal title abbreviation: Curr Opin Gastroenterol
publication date: 2004-03-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.
PubMed Identifier: 15853160
author list: Griffin JM, Amand MS, Demetri GD
published in: Clinical journal of oncology nursing
information resource reference: Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors. Clin J Oncol Nurs. 2005 Apr; 9(2):161-9.
journal title abbreviation: Clin J Oncol Nurs
publication date: 2005-04-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
PubMed Identifier: 16110008
author list: Garcia-Carbonero R, Supko JG, Maki RG, Manola J, Ryan DP, Harmon D, Puchalski TA, Goss G, Seiden MV, Waxman A, Quigley MT, Lopez T, Sancho MA, Jimeno J, Guzman C, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005 Aug 20; 23(24):5484-92.
journal title abbreviation: J Clin Oncol
publication date: 2005-08-20T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
PubMed Identifier: 16954519
author list: Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006 Oct 10; 24(29):4764-74.
journal title abbreviation: J Clin Oncol
publication date: 2006-09-05T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Major developments in the understanding and treatment of soft-tissue sarcomas in adults.
PubMed Identifier: 9702402
author list: Demetri GD
published in: Current opinion in oncology
information resource reference: Major developments in the understanding and treatment of soft-tissue sarcomas in adults. Curr Opin Oncol. 1998 Jul; 10(4):343-7.
journal title abbreviation: Curr Opin Oncol
publication date: 1998-07-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
PubMed Identifier: 12181401
author list: Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H
published in: The New England journal of medicine
information resource reference: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15; 347(7):472-80.
journal title abbreviation: N Engl J Med
publication date: 2002-08-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
PubMed Identifier: 11234874
author list: Ryan DP, Supko JG, Eder JP, Seiden MV, Demetri G, Lynch TJ, Fischman AJ, Davis J, Jimeno J, Clark JW
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res. 2001 Feb; 7(2):231-42.
journal title abbreviation: Clin Cancer Res
publication date: 2001-02-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy.
PubMed Identifier: 11308272
author list: Demetri GD
published in: British journal of cancer
information resource reference: Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy. Br J Cancer. 2001 Apr; 84 Suppl 1:31-7.
journal title abbreviation: Br J Cancer
publication date: 2001-04-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.
PubMed Identifier: 11526490
author list: Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD
published in: Oncogene
information resource reference: STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene. 2001 Aug 16; 20(36):5054-8.
journal title abbreviation: Oncogene
publication date: 2001-08-16T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography.
PubMed Identifier: 14640768
author list: Janicek MJ, Demetri G, Janicek MR, Shaffer K, Fauci MA
published in: Technology in cancer research & treatment
information resource reference: Dynamic infrared imaging of newly diagnosed malignant lymphoma compared with Gallium-67 and Fluorine-18 fluorodeoxyglucose (FDG) positron emission tomography. Technol Cancer Res Treat. 2003 Dec; 2(6):571-8.
journal title abbreviation: Technol Cancer Res Treat
publication date: 2003-12-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Myeloid growth factors clinical practice guidelines in oncology.
PubMed Identifier: 16038645
author list: Crawford J, Althaus B, Armitage J, Blayney DW, Cataland S, Dale DC, Demetri GD, Foran J, Heaney ML, Htoy S, Kloth DD, Lyman GH, Michaud L, Motl S, Vadhan-Raj S, Wong MK
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Myeloid growth factors clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul; 3(4):540-55.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2005-07-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome.
PubMed Identifier: 10400040
author list: Baldini EH, Demetri GD, Fletcher CD, Foran J, Marcus KC, Singer S
published in: Annals of surgery
information resource reference: Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg. 1999 Jul; 230(1):79-86.
journal title abbreviation: Ann Surg
publication date: 1999-07-01T00:00:00
year: 1999
type: Academic Article
type: Article
type: Document
type: Information Resource

A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
PubMed Identifier: 11308270
author list: Glaspy J, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Rigas J, Kuter D, Harmon D, Prow D, Demetri G, Gordon D, Arseneau J, Saven A, Hynes H, Boccia R, O'Byrne J, Colowick AB
published in: British journal of cancer
information resource reference: A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br J Cancer. 2001 Apr; 84 Suppl 1:17-23.
journal title abbreviation: Br J Cancer
publication date: 2001-04-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.
PubMed Identifier: 21173220
author list: Janeway KA, Kim SY, Lodish M, Nosé V, Rustin P, Gaal J, Dahia PL, Liegl B, Ball ER, Raygada M, Lai AH, Kelly L, Hornick JL, O'Sullivan M, de Krijger RR, Dinjens WN, Demetri GD, Antonescu CR, Fletcher JA, Helman L, Stratakis CA
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A. 2011 Jan 04; 108(1):314-8.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2010-12-20T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Imaging features of bone metastases in patients with gastrointestinal stromal tumors.
PubMed Identifier: 22407696
author list: Jati A, Tatli S, Morgan JA, Glickman JN, Demetri GD, Van den Abbele A, Silverman SG
published in: Diagnostic and interventional radiology (Ankara, Turkey)
information resource reference: Imaging features of bone metastases in patients with gastrointestinal stromal tumors. Diagn Interv Radiol. 2012 Jul-Aug; 18(4):391-6.
journal title abbreviation: Diagn Interv Radiol
publication date: 2012-03-09T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

ET-743: the US experience in sarcomas of soft tissues.
PubMed Identifier: 12173492
author list: Demetri GD
published in: Anti-cancer drugs
information resource reference: ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs. 2002 May; 13 Suppl 1:S7-9.
journal title abbreviation: Anticancer Drugs
publication date: 2002-05-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

PDGFRA activating mutations in gastrointestinal stromal tumors.
PubMed Identifier: 12522257
author list: Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD, Fletcher JA
published in: Science (New York, N.Y.)
information resource reference: PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003 Jan 31; 299(5607):708-10.
journal title abbreviation: Science
publication date: 2003-01-09T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
PubMed Identifier: 17385194
author list: Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S
published in: Cancer
information resource reference: Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 01; 109(9):1863-9.
journal title abbreviation: Cancer
publication date: 2007-05-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical management of gastrointestinal stromal tumors: before and after STI-571.
PubMed Identifier: 12094371
author list: Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G
published in: Human pathology
information resource reference: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002 May; 33(5):466-77.
journal title abbreviation: Hum Pathol
publication date: 2002-05-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation.
PubMed Identifier: 11108307
author list: Fields KK, Crump M, Bence-Bruckler I, Bernstein S, Williams S, Frankel S, Miller A, Demetri G, Nabholtz JM, Cruickshank S, Lill M
published in: Bone marrow transplantation
information resource reference: Use of PEG-rHuMGDF in platelet engraftment after autologous stem cell transplantation. Bone Marrow Transplant. 2000 Nov; 26(10):1083-8.
journal title abbreviation: Bone Marrow Transplant
publication date: 2000-11-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
PubMed Identifier: 11719439
author list: Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA
published in: Cancer research
information resource reference: KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001 Nov 15; 61(22):8118-21.
journal title abbreviation: Cancer Res
publication date: 2001-11-15T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

GIST 1, chemotherapy 0, with a brand new hitter up next.
PubMed Identifier: 12197245
author list: Demetri GD
published in: Cancer investigation
information resource reference: GIST 1, chemotherapy 0, with a brand new hitter up next. Cancer Invest. 2002; 20(5-6):853-4.
journal title abbreviation: Cancer Invest
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
PubMed Identifier: 12416897
author list: Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS
published in: Cancer journal (Sudbury, Mass.)
information resource reference: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 2002 Sep-Oct; 8(5):395-9.
journal title abbreviation: Cancer J
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail?
PubMed Identifier: 1692086
author list: Demetri GD, Griffin JD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Hematopoietic growth factors and high-dose chemotherapy: will grams succeed where milligrams fail? J Clin Oncol. 1990 May; 8(5):761-4.
journal title abbreviation: J Clin Oncol
publication date: 1990-05-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
PubMed Identifier: 12637463
author list: Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006.
journal title abbreviation: J Clin Oncol
publication date: 2003-03-15T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor.
PubMed Identifier: 18029844
author list: Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD
published in: AJR. American journal of roentgenology
information resource reference: CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol. 2007 Dec; 189(6):W324-30.
journal title abbreviation: AJR Am J Roentgenol
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.
PubMed Identifier: 12020395
author list: Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J
published in: Clinical breast cancer
information resource reference: Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51.
journal title abbreviation: Clin Breast Cancer
publication date: 2002-04-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Pharmacologic treatment options in patients with thrombocytopenia.
PubMed Identifier: 10831284
author list: Demetri GD
published in: Seminars in hematology
information resource reference: Pharmacologic treatment options in patients with thrombocytopenia. Semin Hematol. 2000 Apr; 37(2 Suppl 4):11-8.
journal title abbreviation: Semin Hematol
publication date: 2000-04-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins.
PubMed Identifier: 2473156
author list: Tedder TF, Isaacs CM, Ernst TJ, Demetri GD, Adler DA, Disteche CM
published in: The Journal of experimental medicine
information resource reference: Isolation and chromosomal localization of cDNAs encoding a novel human lymphocyte cell surface molecule, LAM-1. Homology with the mouse lymphocyte homing receptor and other human adhesion proteins. J Exp Med. 1989 Jul 01; 170(1):123-33.
journal title abbreviation: J Exp Med
publication date: 1989-07-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
PubMed Identifier: 17217313
author list: Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G
published in: Clinical drug investigation
information resource reference: Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clin Drug Investig. 2007; 27(2):85-93.
journal title abbreviation: Clin Drug Investig
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
PubMed Identifier: 19451435
author list: Demetri GD, Wang Y, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors. J Clin Oncol. 2009 Jul 01; 27(19):3141-7.
journal title abbreviation: J Clin Oncol
publication date: 2009-05-18T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Tissue factor gene expression in acute myeloblastic leukemia.
PubMed Identifier: 2617479
author list: Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G
published in: Thrombosis research
information resource reference: Tissue factor gene expression in acute myeloblastic leukemia. Thromb Res. 1989 Nov 01; 56(3):425-30.
journal title abbreviation: Thromb Res
publication date: 1989-11-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
PubMed Identifier: 11740803
author list: Demetri GD
published in: Seminars in oncology
information resource reference: Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol. 2001 Oct; 28(5 Suppl 17):19-26.
journal title abbreviation: Semin Oncol
publication date: 2001-10-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel.
PubMed Identifier: 11895894
author list: Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res. 2002 Mar; 8(3):670-8.
journal title abbreviation: Clin Cancer Res
publication date: 2002-03-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials.
PubMed Identifier: 11961196
author list: Glaspy J, Degos L, Dicato M, Demetri GD
published in: The oncologist
information resource reference: Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7(2):126-35.
journal title abbreviation: Oncologist
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN sarcoma practice guidelines. National Comprehensive Cancer Network.
PubMed Identifier: 9699217
author list: Demetri GD, Pollock R, Baker L, Balcerzak S, Casper E, Conrad C, Fein D, Hutchinson R, Schupak K, Spiro I, Wagman L
published in: Oncology (Williston Park, N.Y.)
information resource reference: NCCN sarcoma practice guidelines. National Comprehensive Cancer Network. Oncology (Williston Park). 1998 Jul; 12(7A):183-218.
journal title abbreviation: Oncology (Williston Park)
publication date: 1998-07-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

High-throughput oncogene mutation profiling in human cancer.
PubMed Identifier: 17293865
author list: Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA
published in: Nature genetics
information resource reference: High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
journal title abbreviation: Nat Genet
publication date: 2007-02-11T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes.
PubMed Identifier: 2212010
author list: Demetri GD, Ernst TJ, Pratt ES, Zenzie BW, Rheinwald JG, Griffin JD
published in: The Journal of clinical investigation
information resource reference: Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. J Clin Invest. 1990 Oct; 86(4):1261-9.
journal title abbreviation: J Clin Invest
publication date: 1990-10-01T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.
PubMed Identifier: 17624289
author list: Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, Gronchi A, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalcberg J
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007 Jul; 5 Suppl 2:S1-29; quiz S30.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
PubMed Identifier: 17546049
author list: Bauer S, Duensing A, Demetri GD, Fletcher JA
published in: Oncogene
information resource reference: KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene. 2007 Nov 29; 26(54):7560-8.
journal title abbreviation: Oncogene
publication date: 2007-06-04T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations.
PubMed Identifier: 17570804
author list: Wray RJ, Stryker JE, Winer E, Demetri G, Emmons KM
published in: Journal of cancer education : the official journal of the American Association for Cancer Education
information resource reference: Do cancer patients fully understand clinical trial participation? A pilot study to assess informed consent and patient expectations. J Cancer Educ. 2007; 22(1):21-4.
journal title abbreviation: J Cancer Educ
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
PubMed Identifier: 16982758
author list: Bauer S, Yu LK, Demetri GD, Fletcher JA
published in: Cancer research
information resource reference: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006 Sep 15; 66(18):9153-61.
journal title abbreviation: Cancer Res
publication date: 2006-09-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma.
PubMed Identifier: 10097144
author list: Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, Spiegelman BM, Singer S
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30; 96(7):3951-6.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 1999-03-30T00:00:00
year: 1999
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
PubMed Identifier: 15355900
author list: Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res. 2004 Sep 01; 10(17):5732-40.
journal title abbreviation: Clin Cancer Res
publication date: 2004-09-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature.
PubMed Identifier: 11145246
author list: Cibas ES, Goss GA, Kulke MH, Demetri GD, Fletcher CD
published in: The American journal of surgical pathology
information resource reference: Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney: a case report and review of the literature. Am J Surg Pathol. 2001 Jan; 25(1):121-6.
journal title abbreviation: Am J Surg Pathol
publication date: 2001-01-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
PubMed Identifier: 19326424
author list: Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD
published in: Pediatric blood & cancer
information resource reference: Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib. Pediatr Blood Cancer. 2009 Jul; 52(7):767-71.
journal title abbreviation: Pediatr Blood Cancer
publication date: 2009-07-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases.
PubMed Identifier: 18451237
author list: Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, Soulieres D, Dirnhofer S, Harlow A, Town A, McKinley A, Supple SG, Seymour J, Di Scala L, van Oosterom A, Herrmann R, Nikolova Z, McArthur AG
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008 May 01; 14(9):2717-25.
journal title abbreviation: Clin Cancer Res
publication date: 2008-05-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors.
PubMed Identifier: 22508822
author list: Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012 May 20; 30(15):1849-56.
journal title abbreviation: J Clin Oncol
publication date: 2012-04-16T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
PubMed Identifier: 22595799
author list: van der Graaf WT, Blay JY, Chawla SP, Kim DW, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P
published in: Lancet (London, England)
information resource reference: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19; 379(9829):1879-86.
journal title abbreviation: Lancet
publication date: 2012-05-16T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 993520
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/84205085

https://connects.catalyst.harvard.edu/Profiles/profile/84205085
PubMed Identifier: 28651804
author list: Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD
published in: Gynecologic oncology
information resource reference: Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. Gynecol Oncol. 2017 09; 146(3):531-537.
journal title abbreviation: Gynecol Oncol
publication date: 2017-06-24T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Myeloid growth factors.
PubMed Identifier: 19176207
author list: Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR, Dale DC, Demetri GD, Erba HP, Foran J, Freifeld AG, Goemann M, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, Michaud LB, Miyata SC, Tallman MS, Vadhan-Raj S, Westervelt P, Wong MK
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Myeloid growth factors. J Natl Compr Canc Netw. 2009 Jan; 7(1):64-83.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2009-01-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical benefits of epoetin alfa therapy in patients with lung cancer.
PubMed Identifier: 14662041
author list: Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J
published in: Clinical lung cancer
information resource reference: Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90.
journal title abbreviation: Clin Lung Cancer
publication date: 2002-02-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass.
PubMed Identifier: 15496628
author list: Demetri GD, Titton RL, Ryan DP, Fletcher CD
published in: The New England journal of medicine
information resource reference: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass. N Engl J Med. 2004 Oct 21; 351(17):1779-87.
journal title abbreviation: N Engl J Med
publication date: 2004-10-21T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret.
PubMed Identifier: 16242898
author list: Stryker JE, Wray RJ, Emmons KM, Winer E, Demetri G
published in: Patient education and counseling
information resource reference: Understanding the decisions of cancer clinical trial participants to enter research studies: factors associated with informed consent, patient satisfaction, and decisional regret. Patient Educ Couns. 2006 Oct; 63(1-2):104-9.
journal title abbreviation: Patient Educ Couns
publication date: 2005-10-19T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Ecdysteroid-inducible polypeptides in a Drosophila cell line.
PubMed Identifier: 6780196
author list: Savakis C, Demetri G, Cherbas P
published in: Cell
information resource reference: Ecdysteroid-inducible polypeptides in a Drosophila cell line. Cell. 1980 Dec; 22(3):665-74.
journal title abbreviation: Cell
publication date: 1980-12-01T00:00:00
year: 1980
type: Academic Article
type: Article
type: Document
type: Information Resource

Current management of metastatic gastrointestinal stromal tumor: a case report.
PubMed Identifier: 16227963
author list: George S, Hornick JL, Bertagnolli MM, Fletcher CD, Demetri GD
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Current management of metastatic gastrointestinal stromal tumor: a case report. Clin Adv Hematol Oncol. 2003 Jan; 1(1):63-4; discussion 65.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2003-01-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors.
PubMed Identifier: 2200537
author list: Sharkis SJ, Jones RJ, Bellis ML, Demetri GD, Griffin JD, Civin C, May WS
published in: Blood
information resource reference: The action of bryostatin on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood. 1990 Aug 15; 76(4):716-20.
journal title abbreviation: Blood
publication date: 1990-08-15T00:00:00
year: 1990
type: Academic Article
type: Article
type: Document
type: Information Resource

Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
PubMed Identifier: 18060025
author list: Demetri GD
published in: The Journal of clinical investigation
information resource reference: Structural reengineering of imatinib to decrease cardiac risk in cancer therapy. J Clin Invest. 2007 Dec; 117(12):3650-3.
journal title abbreviation: J Clin Invest
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/856270
PubMed Identifier: 18955451
author list: Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C, Benjamin RS, Bramwell VH, Demetri GD, Bertagnolli MM, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008 Nov 20; 26(33):5360-7.
journal title abbreviation: J Clin Oncol
publication date: 2008-10-27T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Small molecule tyrosine kinase inhibitor and depression.
PubMed Identifier: 19064960
author list: Quek R, Morgan JA, George S, Butrynski JE, Polson K, Meyer F, Demetri GD, Block SD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Small molecule tyrosine kinase inhibitor and depression. J Clin Oncol. 2009 Jan 10; 27(2):312-3.
journal title abbreviation: J Clin Oncol
publication date: 2008-12-08T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Stem cell factor is a potent synergistic factor in hematopoiesis.
PubMed Identifier: 7515171
author list: Morstyn G, Brown S, Gordon M, Crawford J, Demetri G, Rich W, McGuire B, Foote M, McNiece I
published in: Oncology
information resource reference: Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology. 1994 Mar-Apr; 51(2):205-14.
journal title abbreviation: Oncology
publication date: 1994-03-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Myelosuppression and "conventional" chemotherapy: what price, what benefit?
PubMed Identifier: 8418220
author list: Canellos GP, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Myelosuppression and "conventional" chemotherapy: what price, what benefit? J Clin Oncol. 1993 Jan; 11(1):1-2.
journal title abbreviation: J Clin Oncol
publication date: 1993-01-01T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.
PubMed Identifier: 8461475
author list: Rabinowe SN, Neuberg D, Bierman PJ, Vose JM, Nemunaitis J, Singer JW, Freedman AS, Mauch P, Demetri G, Onetto N
published in: Blood
information resource reference: Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies. Blood. 1993 Apr 01; 81(7):1903-8.
journal title abbreviation: Blood
publication date: 1993-04-01T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
PubMed Identifier: 17062700
author list: Loughrey MB, Waring PM, Dobrovic A, Demetri G, Kovalenko S, McArthur G
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6205-6; author reply 6206-7.
journal title abbreviation: Clin Cancer Res
publication date: 2006-10-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.
PubMed Identifier: 9779721
author list: Demetri GD, Kris M, Wade J, Degos L, Cella D
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998 Oct; 16(10):3412-25.
journal title abbreviation: J Clin Oncol
publication date: 1998-10-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance.
PubMed Identifier: 17452978
author list: Zhu MJ, Ou WB, Fletcher CD, Cohen PS, Demetri GD, Fletcher JA
published in: Oncogene
information resource reference: KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance. Oncogene. 2007 Sep 27; 26(44):6386-95.
journal title abbreviation: Oncogene
publication date: 2007-04-23T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
PubMed Identifier: 18942073
author list: Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M
published in: Journal of surgical oncology
information resource reference: Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009 Jan 01; 99(1):42-7.
journal title abbreviation: J Surg Oncol
publication date: 2009-01-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells.
PubMed Identifier: 2453374
author list: Young DC, Demetri GD, Ernst TJ, Cannistra SA, Griffin JD
published in: Experimental hematology
information resource reference: In vitro expression of colony-stimulating factor genes by human acute myeloblastic leukemia cells. Exp Hematol. 1988 Jun; 16(5):378-82.
journal title abbreviation: Exp Hematol
publication date: 1988-06-01T00:00:00
year: 1988
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.
PubMed Identifier: 22067397
author list: Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012 01 01; 30(1):78-84.
journal title abbreviation: J Clin Oncol
publication date: 2011-11-07T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/869089
PubMed Identifier: 22203182
author list: Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M, Eisenberg BL
published in: Annals of surgical oncology
information resource reference: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol. 2012 Apr; 19(4):1074-80.
journal title abbreviation: Ann Surg Oncol
publication date: 2011-12-28T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.

NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement.
PubMed Identifier: 22203777
author list: Engstrom PF, Bloom MG, Demetri GD, Febbo PG, Goeckeler W, Ladanyi M, Loy B, Murphy K, Nerenberg M, Papagni P, Robson M, Sweetman RW, Tunis S, Demartino J, Larsen JK
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN molecular testing white paper: effectiveness, efficiency, and reimbursement. J Natl Compr Canc Netw. 2011 Dec; 9 Suppl 6:S1-16.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2011-12-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
PubMed Identifier: 22749255
author list: Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. Eur J Cancer. 2012 Nov; 48(16):3036-44.
journal title abbreviation: Eur J Cancer
publication date: 2012-06-29T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1.
PubMed Identifier: 22785409
author list: de Jesus-Gonzalez N, Robinson E, Penchev R, von Mehren M, Heinrich MC, Tap W, Wang Q, Demetri G, George S, Humphreys BD
published in: American journal of hypertension
information resource reference: Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012 Oct; 25(10):1118-23.
journal title abbreviation: Am J Hypertens
publication date: 2012-07-12T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
PubMed Identifier: 21419931
author list: Demetri GD
published in: Seminars in oncology
information resource reference: Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol. 2011 Apr; 38 Suppl 1:S10-9.
journal title abbreviation: Semin Oncol
publication date: 2011-04-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Aberrant AKT activation drives well-differentiated liposarcoma.
PubMed Identifier: 21930930
author list: Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, Grebliunaite R, Ou WB, Sicinska E, Raut CP, Demetri GD, Perez-Atayde AR, Wagner AJ, Fletcher JA, Fletcher CD, Look AT
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011 Sep 27; 108(39):16386-91.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2011-09-19T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1001515
type: Authorship
author rank in publication: 1
linked author: Demetri, George
linked information resource: Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.

Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.
PubMed Identifier: 28854066
author list: Demetri GD, Schöffski P, Grignani G, Blay JY, Maki RG, Van Tine BA, Alcindor T, Jones RL, D'Adamo DR, Guo M, Chawla S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. J Clin Oncol. 2017 Oct 20; 35(30):3433-3439.
journal title abbreviation: J Clin Oncol
publication date: 2017-08-30T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
PubMed Identifier: 20507881
author list: Schöffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, Hollaender N, Jappe A, Demetri GD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010 Oct; 21(10):1990-1998.
journal title abbreviation: Ann Oncol
publication date: 2010-05-27T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
PubMed Identifier: 12512386
author list: Demetri GD
published in: Hematology/oncology clinics of North America
information resource reference: Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development. Hematol Oncol Clin North Am. 2002 Oct; 16(5):1115-24.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2002-10-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Granulocyte colony-stimulating factor and its receptor.
PubMed Identifier: 1720034
author list: Demetri GD, Griffin JD
published in: Blood
information resource reference: Granulocyte colony-stimulating factor and its receptor. Blood. 1991 Dec 01; 78(11):2791-808.
journal title abbreviation: Blood
publication date: 1991-12-01T00:00:00
year: 1991
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.
PubMed Identifier: 15681532
author list: McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol. 2005 Feb 01; 23(4):866-73.
journal title abbreviation: J Clin Oncol
publication date: 2005-02-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.
PubMed Identifier: 15833985
author list: Shankar S, vanSonnenberg E, Desai J, Dipiro PJ, Van Den Abbeele A, Demetri GD
published in: Radiology
information resource reference: Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology. 2005 Jun; 235(3):892-8.
journal title abbreviation: Radiology
publication date: 2005-04-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
PubMed Identifier: 19282169
author list: George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009 Jul; 45(11):1959-68.
journal title abbreviation: Eur J Cancer
publication date: 2009-03-11T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Hemopoietins and leukemia.
PubMed Identifier: 2561122
author list: Demetri GD, Griffin JD
published in: Hematology/oncology clinics of North America
information resource reference: Hemopoietins and leukemia. Hematol Oncol Clin North Am. 1989 Sep; 3(3):535-53.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 1989-09-01T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
PubMed Identifier: 19967539
author list: Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ
published in: Cancer chemotherapy and pharmacology
information resource reference: Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol. 2010 Jul; 66(2):357-71.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 2009-12-05T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification.
PubMed Identifier: 20162573
author list: Janeway KA, Zhu MJ, Barretina J, Perez-Atayde A, Demetri GD, Fletcher JA
published in: International journal of cancer
information resource reference: Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int J Cancer. 2010 Dec 01; 127(11):2718-22.
journal title abbreviation: Int J Cancer
publication date: 2010-12-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
PubMed Identifier: 21030459
author list: Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA
published in: Cancer research
information resource reference: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010 Dec 15; 70(24):10038-43.
journal title abbreviation: Cancer Res
publication date: 2010-10-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
PubMed Identifier: 21751200
author list: von Mehren M, Rankin C, Goldblum JR, Demetri GD, Bramwell V, Ryan CW, Borden E
published in: Cancer
information resource reference: Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012 Feb 01; 118(3):770-6.
journal title abbreviation: Cancer
publication date: 2011-07-12T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1014997
type: Authorship
author rank in publication: 14
linked author: Demetri, George
linked information resource: SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.

SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
PubMed Identifier: 28945250
author list: Nakayama RT, Pulice JL, Valencia AM, McBride MJ, McKenzie ZM, Gillespie MA, Ku WL, Teng M, Cui K, Williams RT, Cassel SH, Qing H, Widmer CJ, Demetri GD, Irizarry RA, Zhao K, Ranish JA, Kadoch C
published in: Nature genetics
information resource reference: SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters. Nat Genet. 2017 Nov; 49(11):1613-1623.
journal title abbreviation: Nat Genet
publication date: 2017-09-25T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
PubMed Identifier: 22614970
author list: George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
journal title abbreviation: J Clin Oncol
publication date: 2012-05-21T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/899913
PubMed Identifier: 7799046
author list: Bajorin DF, Nichols CR, Schmoll HJ, Kantoff PW, Bokemeyer C, Demetri GD, Einhorn LH, Bosl GJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial. J Clin Oncol. 1995 Jan; 13(1):79-86.
journal title abbreviation: J Clin Oncol
publication date: 1995-01-01T00:00:00
year: 1995
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial.

Two patients with sarcoma. Case 2. Uterine sarcoma.
PubMed Identifier: 10829056
author list: Blobe GC, Mantel M, Janicek M, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Two patients with sarcoma. Case 2. Uterine sarcoma. J Clin Oncol. 2000 Jun; 18(11):2343-4.
journal title abbreviation: J Clin Oncol
publication date: 2000-06-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
PubMed Identifier: 11839653
author list: Bramwell VH, Morris D, Ernst DS, Hings I, Blackstein M, Venner PM, Ette EI, Harding MW, Waxman A, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res. 2002 Feb; 8(2):383-93.
journal title abbreviation: Clin Cancer Res
publication date: 2002-02-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.
PubMed Identifier: 12209734
author list: Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA
published in: Cancer
information resource reference: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15; 95(4):888-95.
journal title abbreviation: Cancer
publication date: 2002-08-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/903562
PubMed Identifier: 12357306
author list: Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, Seiden MV, Maki RG, Lopez-Lazaro L, Jimeno J, Guzman C, Supko JG
published in: Cancer chemotherapy and pharmacology
information resource reference: Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol. 2002 Oct; 50(4):309-19.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 2002-07-31T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.

Challenges in the development of platelet growth factors: low expectations for low counts.
PubMed Identifier: 12901132
author list: Brown JR, Demetri GD
published in: Current hematology reports
information resource reference: Challenges in the development of platelet growth factors: low expectations for low counts. Curr Hematol Rep. 2002 Nov; 1(2):110-8.
journal title abbreviation: Curr Hematol Rep
publication date: 2002-11-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
PubMed Identifier: 16326753
author list: Herbst RS, Bajorin DF, Bleiberg H, Blum D, Hao D, Johnson BE, Ozols RF, Demetri GD, Ganz PA, Kris MG, Levin B, Markman M, Raghavan D, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Vokes EE, Winn RJ, Mayer RJ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006 Jan 01; 24(1):190-205.
journal title abbreviation: J Clin Oncol
publication date: 2005-12-02T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

NCCN: New applications for erythropoietin.
PubMed Identifier: 11760562
author list: Demetri GD
published in: Cancer control : journal of the Moffitt Cancer Center
information resource reference: NCCN: New applications for erythropoietin. Cancer Control. 2001 Nov-Dec; 8(6 Suppl 2):72-6.
journal title abbreviation: Cancer Control
publication date: 2001-11-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
PubMed Identifier: 14645423
author list: Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, McGreevey LS, Chen CJ, Van den Abbeele AD, Druker BJ, Kiese B, Eisenberg B, Roberts PJ, Singer S, Fletcher CD, Silberman S, Dimitrijevic S, Fletcher JA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003 Dec 01; 21(23):4342-9.
journal title abbreviation: J Clin Oncol
publication date: 2003-12-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
PubMed Identifier: 16710031
author list: Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24(15):2325-31.
journal title abbreviation: J Clin Oncol
publication date: 2006-05-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas.
PubMed Identifier: 17256054
author list: Li D, Ji H, Zaghlul S, McNamara K, Liang MC, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Scott AM, Jungbluth AA, Cavenee WK, Old LJ, Demetri GD, Wong KK
published in: The Journal of clinical investigation
information resource reference: Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J Clin Invest. 2007 Feb; 117(2):346-52.
journal title abbreviation: J Clin Invest
publication date: 2007-01-25T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Soft tissue sarcoma.
PubMed Identifier: 17442230
author list: Demetri GD, Baker LH, Benjamin RS, Casper ES, Conrad EU, D'Amato GZ, DeLaney TF, Ettinger DS, Heck R, Heslin MJ, Hutchinson RJ, Jacobs CD, Kiel K, Kraybill WG, Letson GD, O'Donnell RJ, Paz IB, Pfeifer J, Pollock RE, Randall RL, Sasson AR, Schupak KD, Tyler DS, von Mehren M, Wayne J
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Soft tissue sarcoma. J Natl Compr Canc Netw. 2007 Apr; 5(4):364-99.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2007-04-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
PubMed Identifier: 18235121
author list: Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, Corless CL, Fletcher CD, Roberts PJ, Heinz D, Wehre E, Nikolova Z, Joensuu H
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008 Feb 01; 26(4):620-5.
journal title abbreviation: J Clin Oncol
publication date: 2008-02-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma.
PubMed Identifier: 21642514
author list: Gronchi A, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Pérez I, Nieto A, Tercero JC, Alfaro V, Tamborini E, Blay JY
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012 Mar; 23(3):771-776.
journal title abbreviation: Ann Oncol
publication date: 2011-06-03T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Update on new diagnostic and therapeutic approaches for sarcomas.
PubMed Identifier: 16258489
author list: Dileo P, Demetri GD
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol. 2005 Oct; 3(10):781-91.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2005-10-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma.
PubMed Identifier: 11505068
author list: Esnaola NF, Rubin BP, Baldini EH, Vasudevan N, Demetri GD, Fletcher CD, Singer S
published in: Annals of surgery
information resource reference: Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001 Aug; 234(2):215-23.
journal title abbreviation: Ann Surg
publication date: 2001-08-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma.
PubMed Identifier: 12910529
author list: Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D
published in: Cancer
information resource reference: Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003 Aug 15; 98(4):832-40.
journal title abbreviation: Cancer
publication date: 2003-08-15T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred.
PubMed Identifier: 15837988
author list: Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C, Duensing A, van de Rijn M, Schnipper LE, Demetri GD
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005 Apr 20; 23(12):2735-43.
journal title abbreviation: J Clin Oncol
publication date: 2005-04-20T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1029742
type: Authorship
author rank in publication: 15
linked author: Demetri, George
linked information resource: Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.

Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial.
PubMed Identifier: 29177975
author list: Calvo E, Azaro A, Rodon J, Dirix L, Huizing M, Senecal FM, LoRusso P, Yee L, Poggesi I, de Jong J, Triantos S, Park YC, Knoblauch RE, Parekh TV, Demetri GD, von Mehren M
published in: Investigational new drugs
information resource reference: Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. Invest New Drugs. 2018 06; 36(3):476-486.
journal title abbreviation: Invest New Drugs
publication date: 2017-11-27T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/938640
PubMed Identifier: 18234424
author list: Liu MC, Demetri GD, Berry DA, Norton L, Broadwater G, Robert NJ, Duggan D, Hayes DF, Henderson IC, Lyss A, Hopkins J, Kaufman PA, Marcom PK, Younger J, Lin N, Tkaczuk K, Winer EP, Hudis CA
published in: Cancer treatment reviews
information resource reference: Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
journal title abbreviation: Cancer Treat Rev
publication date: 2008-01-30T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
PubMed Identifier: 18623623
author list: Liegl B, Kepten I, Le C, Zhu M, Demetri GD, Heinrich MC, Fletcher CD, Corless CL, Fletcher JA
published in: The Journal of pathology
information resource reference: Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008 Sep; 216(1):64-74.
journal title abbreviation: J Pathol
publication date: 2008-09-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
PubMed Identifier: 22347360
author list: Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK
published in: PloS one
information resource reference: Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One. 2012; 7(2):e26331.
journal title abbreviation: PLoS One
publication date: 2012-02-07T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression.
PubMed Identifier: 7986706
author list: Tepler I, Elias A, Kalish L, Shulman L, Strauss G, Skarin A, Lynch T, Levitt D, Resta D, Demetri G
published in: British journal of haematology
information resource reference: Effect of recombinant human interleukin-3 on haematological recovery from chemotherapy-induced myelosuppression. Br J Haematol. 1994 Aug; 87(4):678-86.
journal title abbreviation: Br J Haematol
publication date: 1994-08-01T00:00:00
year: 1994
type: Academic Article
type: Article
type: Document
type: Information Resource

Advances in the treatment of gastrointestinal stromal tumours.
PubMed Identifier: 17761719
author list: Judson I, Demetri G
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Advances in the treatment of gastrointestinal stromal tumours. Ann Oncol. 2007 Sep; 18 Suppl 10:x20-4.
journal title abbreviation: Ann Oncol
publication date: 2007-09-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors.
PubMed Identifier: 17875769
author list: Desai J, Shankar S, Heinrich MC, Fletcher JA, Fletcher CD, Manola J, Morgan JA, Corless CL, George S, Tuncali K, Silverman SG, Van den Abbeele AD, van Sonnenberg E, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5398-405.
journal title abbreviation: Clin Cancer Res
publication date: 2007-09-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Leiomyosarcoma of the inferior vena cava: survival after aggressive management.
PubMed Identifier: 17896156
author list: Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP
published in: Annals of surgical oncology
information resource reference: Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007 Dec; 14(12):3534-41.
journal title abbreviation: Ann Surg Oncol
publication date: 2007-09-25T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
PubMed Identifier: 18086794
author list: Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2008 Jan 10; 26(2):313-25.
journal title abbreviation: J Clin Oncol
publication date: 2007-12-17T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.
PubMed Identifier: 18927287
author list: Girnun GD, Chen L, Silvaggi J, Drapkin R, Chirieac LR, Padera RF, Upadhyay R, Vafai SB, Weissleder R, Mahmood U, Naseri E, Buckley S, Li D, Force J, McNamara K, Demetri G, Spiegelman BM, Wong KK
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res. 2008 Oct 15; 14(20):6478-86.
journal title abbreviation: Clin Cancer Res
publication date: 2008-10-15T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.
PubMed Identifier: 20121601
author list: Rubin BP, Blanke CD, Demetri GD, Dematteo RP, Fletcher CD, Goldblum JR, Lasota J, Lazar A, Maki RG, Miettinen M, Noffsinger A, Washington MK, Krausz T
published in: Archives of pathology & laboratory medicine
information resource reference: Protocol for the examination of specimens from patients with gastrointestinal stromal tumor. Arch Pathol Lab Med. 2010 Feb; 134(2):165-70.
journal title abbreviation: Arch Pathol Lab Med
publication date: 2010-02-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Multimodality treatment of mesenteric desmoid tumours.
PubMed Identifier: 18706807
author list: Bertagnolli MM, Morgan JA, Fletcher CD, Raut CP, Dileo P, Gill RR, Demetri GD, George S
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Multimodality treatment of mesenteric desmoid tumours. Eur J Cancer. 2008 Nov; 44(16):2404-10.
journal title abbreviation: Eur J Cancer
publication date: 2008-08-14T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
PubMed Identifier: 19737946
author list: Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH, Bello CL, Huang X, Cohen DP, Baum CM, Maki RG
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5902-9.
journal title abbreviation: Clin Cancer Res
publication date: 2009-09-08T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
PubMed Identifier: 19789325
author list: Demetri GD, Lo Russo P, MacPherson IR, Wang D, Morgan JA, Brunton VG, Paliwal P, Agrawal S, Voi M, Evans TR
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res. 2009 Oct 01; 15(19):6232-40.
journal title abbreviation: Clin Cancer Res
publication date: 2009-09-29T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
PubMed Identifier: 19805684
author list: Theman TA, Hartzell TL, Sinha I, Polson K, Morgan J, Demetri GD, Orgill DP, George S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage. J Clin Oncol. 2009 Nov 20; 27(33):e198-200.
journal title abbreviation: J Clin Oncol
publication date: 2009-10-05T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/958071
PubMed Identifier: 23177515
author list: Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG
published in: Lancet (London, England)
information resource reference: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26; 381(9863):295-302.
journal title abbreviation: Lancet
publication date: 2012-11-22T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines.
PubMed Identifier: 23573667
author list: Demetri GD, Benjamin R, Blanke CD, Choi H, Corless C, DeMatteo RP, Eisenberg BL, Fletcher CD, Maki RG, Rubin BP, Van den Abbeele AD, von Mehren M
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)--expansion and update of NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2004 May; 2 Suppl 1:S-1-26; quiz 27-30.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2004-05-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
PubMed Identifier: 19737953
author list: Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res. 2009 Sep 15; 15(18):5869-77.
journal title abbreviation: Clin Cancer Res
publication date: 2009-09-08T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma.
PubMed Identifier: 8401592
author list: Park S, Schalling M, Bernard A, Maheswaran S, Shipley GC, Roberts D, Fletcher J, Shipman R, Rheinwald J, Demetri G
published in: Nature genetics
information resource reference: The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993 Aug; 4(4):415-20.
journal title abbreviation: Nat Genet
publication date: 1993-08-01T00:00:00
year: 1993
type: Academic Article
type: Article
type: Document
type: Information Resource

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
PubMed Identifier: 19303137
author list: Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K
published in: Lancet (London, England)
information resource reference: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009 Mar 28; 373(9669):1097-104.
journal title abbreviation: Lancet
publication date: 2009-03-18T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro.
PubMed Identifier: 2787682
author list: Demetri GD, Zenzie BW, Rheinwald JG, Griffin JD
published in: Blood
information resource reference: Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood. 1989 Aug 15; 74(3):940-6.
journal title abbreviation: Blood
publication date: 1989-08-15T00:00:00
year: 1989
type: Academic Article
type: Article
type: Document
type: Information Resource

mTOR inhibitors in sarcoma.
PubMed Identifier: 22379663
author list: Demetri GD
published in: Clinical advances in hematology & oncology : H&O
information resource reference: mTOR inhibitors in sarcoma. Clin Adv Hematol Oncol. 2011 Feb; 9(2):145-7.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2011-02-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
PubMed Identifier: 22858558
author list: George S, Reichardt P, Lechner T, Li S, Cohen DP, Demetri GD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. Ann Oncol. 2012 Dec; 23(12):3180-3187.
journal title abbreviation: Ann Oncol
publication date: 2012-08-02T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Modifying phase I methodology to facilitate enrolment of molecularly selected patients.
PubMed Identifier: 23333057
author list: Hollebecque A, Postel-Vinay S, Verweij J, Demetri GD, Flaherty K, Bedard P, Soria JC
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: Modifying phase I methodology to facilitate enrolment of molecularly selected patients. Eur J Cancer. 2013 May; 49(7):1515-20.
journal title abbreviation: Eur J Cancer
publication date: 2013-01-16T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Hematopoietic growth factors: current knowledge, future prospects.
PubMed Identifier: 1382921
author list: Demetri GD
published in: Current problems in cancer
information resource reference: Hematopoietic growth factors: current knowledge, future prospects. Curr Probl Cancer. 1992 Jul-Aug; 16(4):177-259.
journal title abbreviation: Curr Probl Cancer
publication date: 1992-07-01T00:00:00
year: 1992
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 100323
type: Authorship
author rank in publication: 17
linked author: Demetri, George
linked information resource: CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans.

Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
PubMed Identifier: 14706663
author list: Adams JR, Elting LS, Lyman GH, George JN, Lembersky BC, Armitage JO, Demetri GD, Bennett CL
published in: The American journal of medicine
information resource reference: Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries. Am J Med. 2004 Jan 01; 116(1):28-34.
journal title abbreviation: Am J Med
publication date: 2004-01-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668.
PubMed Identifier: 15701856
author list: Davis DW, Takamori R, Raut CP, Xiong HQ, Herbst RS, Stadler WM, Heymach JV, Demetri GD, Rashid A, Shen Y, Wen S, Abbruzzese JL, McConkey DJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):678-89.
journal title abbreviation: Clin Cancer Res
publication date: 2005-01-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO.
PubMed Identifier: 15781488
author list: Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A, McClure J, Mac Clure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD
published in: Annals of oncology : official journal of the European Society for Medical Oncology
information resource reference: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005 Apr; 16(4):566-78.
journal title abbreviation: Ann Oncol
publication date: 2005-04-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Diagnosis in oncology. Askin tumor.
PubMed Identifier: 9586920
author list: Amatruda JF, Tran K, Mantel M, Singer S, Demetri G
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Diagnosis in oncology. Askin tumor. J Clin Oncol. 1998 May; 16(5):1997-8.
journal title abbreviation: J Clin Oncol
publication date: 1998-05-01T00:00:00
year: 1998
type: Academic Article
type: Article
type: Document
type: Information Resource

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
PubMed Identifier: 22661587
author list: Demetri GD, Garrett CR, Schöffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res. 2012 Jun 01; 18(11):3170-9.
journal title abbreviation: Clin Cancer Res
publication date: 2012-06-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of malignant gastrointestinal stromal tumours.
PubMed Identifier: 12424067
author list: Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G
published in: The Lancet. Oncology
information resource reference: Management of malignant gastrointestinal stromal tumours. Lancet Oncol. 2002 Nov; 3(11):655-64.
journal title abbreviation: Lancet Oncol
publication date: 2002-11-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource